Breaking News

Saturday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
American Society of Clinical Oncology (ASCO) to hold a symposium » 04:55
01/22/22
01/22
04:55
01/22/22
04:55
AGEN

Agenus

$2.70 /

-0.055 (-2.00%)

, AZN

AstraZeneca

$59.10 /

-1.1 (-1.83%)

, BAYRY

Bayer

$14.62 /

-0.26 (-1.75%)

, BMY

Bristol-Myers

$63.56 /

-1.045 (-1.62%)

, CRDF

Cardiff Oncology

$3.70 /

-0.18 (-4.65%)

, DSNKY

Daiichi Sankyo

$22.66 /

-0.03 (-0.13%)

, DCPH

Deciphera

$8.05 /

-0.1 (-1.23%)

, DNA

Ginkgo Bioworks

$5.27 /

+0.165 (+3.23%)

, ESALY

Eisai

$51.92 /

-0.78 (-1.48%)

, EXAS

Exact Sciences

$74.06 /

-2.005 (-2.64%)

, EXEL

Exelixis

$17.34 /

+0.29 (+1.70%)

, GH

Guardant Health

$70.17 /

-2.36 (-3.25%)

, HCM

Hutchmed

$28.82 /

-1.16 (-3.87%)

, IMMVF

Immunovia

$7.40 /

+ (+0.00%)

, INCY

Incyte

$74.77 /

-0.05 (-0.07%)

, IPSEY

Ipsen

$23.66 /

+0.38 (+1.63%)

, LLY

Eli Lilly

$243.12 /

-0.01 (-0.00%)

, MRK

Merck

$79.98 /

-0.765 (-0.95%)

, MRTX

Mirati Therapeutics

$114.10 /

-4.4 (-3.71%)

, NTRA

Natera

$62.74 /

-0.355 (-0.56%)

, NVCR

Novocure

$67.14 /

-2.9 (-4.14%)

, NVS

Novartis

$87.01 /

-1.18 (-1.34%)

, ORIC

Oric Pharmaceuticals

$10.96 /

-0.37 (-3.27%)

, PBLA

Panbela Therapeutics

$1.60 /

-0.09 (-5.33%)

, PFE

Pfizer

$52.78 /

-1.3 (-2.40%)

, SGEN

Seagen

$127.66 /

-4.85 (-3.66%)

, TPTX

Turning Point Therapeutics

$35.95 /

+0.07 (+0.20%)

, VCYT

Veracyte

$27.00 /

-0.69 (-2.49%)

, ZYME

Zymeworks

$11.20 /

-0.38 (-3.28%)

ASCO Gastrointestinal…

ASCO Gastrointestinal Cancers Symposium to be held in San Francisco on January 20-22. Webcast Link

ShowHide Related Items >><<
ZYME Zymeworks
$11.20 /

-0.38 (-3.28%)

VCYT Veracyte
$27.00 /

-0.69 (-2.49%)

TPTX Turning Point Therapeutics
$35.95 /

+0.07 (+0.20%)

SGEN Seagen
$127.66 /

-4.85 (-3.66%)

PFE Pfizer
$52.78 /

-1.3 (-2.40%)

PBLA Panbela Therapeutics
$1.60 /

-0.09 (-5.33%)

ORIC Oric Pharmaceuticals
$10.96 /

-0.37 (-3.27%)

NVS Novartis
$87.01 /

-1.18 (-1.34%)

NVCR Novocure
$67.14 /

-2.9 (-4.14%)

NTRA Natera
$62.74 /

-0.355 (-0.56%)

MRTX Mirati Therapeutics
$114.10 /

-4.4 (-3.71%)

MRK Merck
$79.98 /

-0.765 (-0.95%)

LLY Eli Lilly
$243.12 /

-0.01 (-0.00%)

IPSEY Ipsen
$23.66 /

+0.38 (+1.63%)

INCY Incyte
$74.77 /

-0.05 (-0.07%)

HCM Hutchmed
$28.82 /

-1.16 (-3.87%)

GH Guardant Health
$70.17 /

-2.36 (-3.25%)

EXEL Exelixis
$17.34 /

+0.29 (+1.70%)

EXAS Exact Sciences
$74.06 /

-2.005 (-2.64%)

ESALY Eisai
$51.92 /

-0.78 (-1.48%)

DSNKY Daiichi Sankyo
$22.66 /

-0.03 (-0.13%)

DNA Ginkgo Bioworks
$5.27 /

+0.165 (+3.23%)

DCPH Deciphera
$8.05 /

-0.1 (-1.23%)

CRDF Cardiff Oncology
$3.70 /

-0.18 (-4.65%)

BMY Bristol-Myers
$63.56 /

-1.045 (-1.62%)

BAYRY Bayer
$14.62 /

-0.26 (-1.75%)

AZN AstraZeneca
$59.10 /

-1.1 (-1.83%)

AGEN Agenus
$2.70 /

-0.055 (-2.00%)

AGEN Agenus
$2.70 /

-0.055 (-2.00%)

12/16/21 H.C. Wainwright
Agenus initiated with a Buy at H.C. Wainwright
12/06/21 B. Riley
B. Riley bullish on Novavax, Agenus amid Omicron spread
11/09/21 Evercore ISI
Evercore starts Agenus spinout MiNK Therapeutics with an Outperform
10/25/21 B. Riley
Agenus price target lowered to $11 from $12 at B. Riley
AZN AstraZeneca
$59.10 /

-1.1 (-1.83%)

12/30/21 SVB Leerink
SVB Leerink confident Adbry poses minimal competitive risk to Dupixent
12/16/21 Morgan Stanley
AstraZeneca price target raised to 10,200 GBp from 10,000 GBp at Morgan Stanley
12/16/21 Stifel
Adagio story 'even more complicated' after preprints on ADG20, says Stifel
12/12/21 Piper Sandler
Schrodinger MALT1 preclinical data supports IND filing in 1H22, says Piper
BAYRY Bayer
$14.62 /

-0.26 (-1.75%)

11/15/21 AlphaValue/Baader
Bayer upgraded to Buy from Add at AlphaValue/Baader
11/10/21 JPMorgan
Bayer price target raised to EUR 75 from EUR 67 at JPMorgan
11/10/21 Morgan Stanley
Bayer price target raised to EUR 74 from EUR 71 at Morgan Stanley
11/10/21 Credit Suisse
Bayer price target raised to EUR 57 from EUR 55 at Credit Suisse
BMY Bristol-Myers
$63.56 /

-1.045 (-1.62%)

01/10/22 Piper Sandler
Piper says Century Therapeutics' alliance with Bristol 'transformational'
01/03/22 Piper Sandler
Legend Biotech named a top pick for 2022 at Piper Sandler
12/21/21 Oppenheimer
Oppenheimer starts Cytokinetics at Outperform, sees 'blockbuster' potential
12/21/21 Piper Sandler
Legend Biotech initiated with an Overweight at Piper Sandler
CRDF Cardiff Oncology
$3.70 /

-0.18 (-4.65%)

12/07/21 Baird
Cardiff Oncology initiated with an Outperform at Baird
11/18/21 Piper Sandler
Cardiff investment by Pfizer 'some nice validation,' says Piper Sandler
09/09/21 Maxim
Cardiff Oncology price target raised to $25 from $20 at Maxim
09/09/21 Piper Sandler
Cardiff colorectal cancer data 'very consistent,' says Piper Sandler
DSNKY Daiichi Sankyo
$22.66 /

-0.03 (-0.13%)

10/27/21 SVB Leerink
Seagen price target raised to $200 from $190 at SVB Leerink
03/15/21 Citi
Citi opens 'positive catalyst watch' on Daiichi Sankyo
03/08/21 Goldman Sachs
Daiichi Sankyo upgraded to Buy from Neutral at Goldman Sachs
DCPH Deciphera
$8.05 /

-0.1 (-1.23%)

12/01/21 H.C. Wainwright
Deciphera price target lowered to $15 from $25 at H.C. Wainwright
11/30/21 Piper Sandler
Deciphera price target lowered to $11 from $14 at Piper Sandler
11/08/21 Barclays
Deciphera downgraded to Equal Weight at Barclays after GIST trial miss
11/08/21 Canaccord
Deciphera downgraded to Hold at Canaccord
DNA Ginkgo Bioworks
$5.27 /

+0.165 (+3.23%)

01/06/22 BTIG
BTIG starts Ginkgo Bioworks at Buy with $12 price target
01/06/22 BTIG
Ginkgo Bioworks initiated with a Buy at BTIG
11/29/21 Jefferies
Ginkgo Bioworks initiated with a Buy at Jefferies
10/20/21 Raymond James
Raymond James expects more equity-based payments for Ginkgo as milestones met
ESALY Eisai
$51.92 /

-0.78 (-1.48%)

01/13/22 Citi
Eisai downgraded to Neutral from Buy at Citi
10/08/21 Jefferies
Biogen price target lowered to $400 from $500 at Jefferies
09/30/21 RBC Capital
Prothena price target raised to $82 from $59 at RBC Capital
06/25/21 Morgan Stanley
Eisai downgraded to Equal Weight from Overweight at Morgan Stanley
EXAS Exact Sciences
$74.06 /

-2.005 (-2.64%)

11/03/21 BTIG
Exact Sciences price target lowered to $120 from $145 at BTIG
11/03/21 Craig-Hallum
Exact Sciences price target lowered to $133 from $144 at Craig-Hallum
11/03/21 Raymond James
Exact Sciences downgraded to Outperform from Strong Buy at Raymond James
11/03/21 Wells Fargo
Exact Sciences price target lowered to $95 from $120 at Wells Fargo
EXEL Exelixis
$17.34 /

+0.29 (+1.70%)

11/18/21 Piper Sandler
Exelixis transferred with Overweight at Piper Sandler
11/03/21 H.C. Wainwright
Exelixis price target lowered to $52 from $65 at H.C. Wainwright
10/06/21 Jefferies
Exelixis initiated with a Buy at Jefferies
08/06/21 H.C. Wainwright
Exelixis price target raised to $64 from $35 at H.C. Wainwright
GH Guardant Health
$70.17 /

-2.36 (-3.25%)

10/14/21 Cowen
Guardant Health coverage transferred at Cowen
08/09/21 Canaccord
Guardant Health price target lowered to $180 from $195 at Canaccord
06/21/21 Wells Fargo
Guardant Health price target raised to $160 from $145 at Wells Fargo
06/15/21
Fly Intel: Top five analyst initiations
HCM Hutchmed
$28.82 /

-1.16 (-3.87%)

09/22/21
Fly Intel: Top five analyst downgrades
09/22/21 Goldman Sachs
Hutchmed downgraded to Neutral from Buy at Goldman Sachs
08/03/21 Jefferies
Hutchmed initiated with a Buy at Jefferies
07/13/21 Cantor Fitzgerald
Hutchmed price target raised to $45 from $40 at Cantor Fitzgerald
IMMVF Immunovia
$7.40 /

+ (+0.00%)

12/22/21 Kempen
Immunovia downgraded to Neutral from Buy at Kempen
INCY Incyte
$74.77 /

-0.05 (-0.07%)

01/18/22 RBC Capital
Incyte upgraded to Outperform at RBC Capital on improving 2022 setup
01/18/22 RBC Capital
Incyte upgraded to Outperform from Sector Perform at RBC Capital
01/03/22 Guggenheim
Incyte price target lowered to $104 from $118 at Guggenheim
12/31/21 Benchmark
Incyte, Nektar, Compass Therapeutics named best biotech picks at Benchmark
IPSEY Ipsen
$23.66 /

+0.38 (+1.63%)

01/11/22 Bryan Garnier
Ipsen upgraded to Buy from Neutral at Bryan Garnier
01/06/22 Societe Generale
Ipsen upgraded to Buy from Hold at Societe Generale
01/04/22 JPMorgan
Ipsen downgraded to Neutral from Overweight at JPMorgan
11/24/21 Berenberg
Ipsen initiated with a Hold at Berenberg
LLY Eli Lilly
$243.12 /

-0.01 (-0.00%)

01/21/22 DZ Bank
Eli Lilly upgraded to Buy from Hold at DZ Bank
01/14/22 BofA
Biogen price target lowered to $245 from $275 at BofA
01/12/22 Wells Fargo
CMS proposed coverage with evidence 'a clear negative,' says Wells Fargo
01/05/22 Mizuho
Eli Lilly price target raised to $302 from $272 at Mizuho
MRK Merck
$79.98 /

-0.765 (-0.95%)

12/23/21 Mizuho
Mizuho sees market for both Merck's molnupiravir, Pfizer's Paxlovid
12/17/21 Goldman Sachs
Goldman starts Merck at Conviction Buy with market undervaluing assets
12/17/21 Goldman Sachs
Merck initiated with a Conviction Buy at Goldman Sachs
12/16/21 Daiwa
Merck initiated with a Neutral at Daiwa
MRTX Mirati Therapeutics
$114.10 /

-4.4 (-3.71%)

11/18/21 BMO Capital
Amgen initiated with a Market Perform at BMO Capital
11/18/21 BMO Capital
Mirati Therapeutics initiated with an Outperform at BMO Capital
09/22/21 Stifel
Mirati Therapeutics initiated with a Buy at Stifel
09/22/21 Citi
Mirati Therapeutics price target raised to $244 from $232 at Citi
NTRA Natera
$62.74 /

-0.355 (-0.56%)

01/12/22 BTIG
Natera price target lowered to $150, named one of top 2022 picks at BTIG
01/05/22 Piper Sandler
Natera assumed with an Overweight at Piper Sandler
01/04/22 Canaccord
Natera weakness a buying opportunity, says Canaccord
11/05/21 Baird
Natera price target raised to $152 from $145 at Baird
NVCR Novocure
$67.14 /

-2.9 (-4.14%)

01/20/22 Truist
Novocure upgraded to Buy on more favorable risk-reward at Truist
01/20/22 Truist
Novocure upgraded to Buy from Hold at Truist
01/11/22 Wells Fargo
Novocure price target lowered to $70 from $105 at Wells Fargo
01/10/22 Piper Sandler
Novocure price target lowered to $125 from $130 at Piper Sandler
NVS Novartis
$87.01 /

-1.18 (-1.34%)

01/12/22 Alliance Global Partners
OpGen price target lowered to $3 from $4.35 at Alliance Global Partners
01/10/22 Citi
Novartis resumed with a Buy at Citi
01/06/22 Piper Sandler
Piper want to own Alnylam shares ahead of expected vutrisiran approval
12/15/21 Berenberg
Novartis price target lowered to CHF 85 from CHF 88 at Berenberg
ORIC Oric Pharmaceuticals
$10.96 /

-0.37 (-3.27%)

10/08/21 Baird
Oric Pharmaceuticals price target lowered to $26 from $47 at Baird
10/08/21 Citi
Oric Pharmaceuticals price target lowered to $22 from $33 at Citi
10/08/21 H.C. Wainwright
Oric Pharmaceuticals price target lowered to $30 from $53 at H.C. Wainwright
10/07/21 Oppenheimer
Oppenheimer remains bullish on Oric Pharmaceuticals, says selloff 'overdone'
PBLA Panbela Therapeutics
$1.60 /

-0.09 (-5.33%)

06/28/21 Roth Capital
Panbela Therapeutics initiated with a Buy at Roth Capital
03/10/21 Maxim
Panbela Therapeutics initiated with a Buy at Maxim
PFE Pfizer
$52.78 /

-1.3 (-2.40%)

01/14/22 BMO Capital
Pfizer price target raised to $76 from $60 at BMO Capital
01/11/22 BofA
Pfizer added to US 1 List; Goldman Sachs removed at BofA
01/10/22 Wedbush
Beam Therapeutics price target raised to $159 from $148 at Wedbush
01/05/22 BofA
Pfizer upgraded to Buy from Neutral at BofA
SGEN Seagen
$127.66 /

-4.85 (-3.66%)

11/08/21 Wolfe Research
Seagen initiated with a Peer Perform at Wolfe Research
10/28/21 Piper Sandler
Seagen price target raised to $165 from $160 at Piper Sandler
10/28/21 Piper Sandler
Seagen price target raised to $165 from $160 at Piper Sandler
TPTX Turning Point Therapeutics
$35.95 /

+0.07 (+0.20%)

01/21/22 Oppenheimer
Turning Point Therapeutics price target lowered to $105 from $115 at Oppenheimer
01/03/22 Guggenheim
Turning Point Therapeutics price target lowered to $107 from $118 at Guggenheim
12/22/21 Roth Capital
Turning Point FDA feedback appears positive, says Roth Capital
12/06/21 Cowen
Turning Point Therapeutics initiated with an Outperform at Cowen
VCYT Veracyte
$27.00 /

-0.69 (-2.49%)

01/06/22 Stephens
Veracyte initiated with Overweight, named best idea at Stephens
11/18/21 Goldman Sachs
Veracyte reinstated with a Buy at Goldman Sachs
11/10/21 Raymond James
Veracyte price target raised to $62 from $50 at Raymond James
06/28/21 Raymond James
Veracyte price target raised to $50 from $45 at Raymond James
ZYME Zymeworks
$11.20 /

-0.38 (-3.28%)

12/10/21 Raymond James
Zymeworks downgraded to Outperform from Strong Buy at Raymond James
12/10/21 SVB Leerink
Zymeworks upgraded to Outperform from Market Perform at SVB Leerink
12/09/21 Raymond James
Zymeworks downgraded to Outperform from Strong Buy at Raymond James
11/17/21 Guggenheim
Zymeworks assumed with a Neutral at Guggenheim
ZYME Zymeworks
$11.20 /

-0.38 (-3.28%)

VCYT Veracyte
$27.00 /

-0.69 (-2.49%)

TPTX Turning Point Therapeutics
$35.95 /

+0.07 (+0.20%)

SGEN Seagen
$127.66 /

-4.85 (-3.66%)

PFE Pfizer
$52.78 /

-1.3 (-2.40%)

PBLA Panbela Therapeutics
$1.60 /

-0.09 (-5.33%)

ORIC Oric Pharmaceuticals
$10.96 /

-0.37 (-3.27%)

NVS Novartis
$87.01 /

-1.18 (-1.34%)

NVCR Novocure
$67.14 /

-2.9 (-4.14%)

NTRA Natera
$62.74 /

-0.355 (-0.56%)

MRTX Mirati Therapeutics
$114.10 /

-4.4 (-3.71%)

MRK Merck
$79.98 /

-0.765 (-0.95%)

LLY Eli Lilly
$243.12 /

-0.01 (-0.00%)

INCY Incyte
$74.77 /

-0.05 (-0.07%)

GH Guardant Health
$70.17 /

-2.36 (-3.25%)

EXEL Exelixis
$17.34 /

+0.29 (+1.70%)

EXAS Exact Sciences
$74.06 /

-2.005 (-2.64%)

DNA Ginkgo Bioworks
$5.27 /

+0.165 (+3.23%)

DCPH Deciphera
$8.05 /

-0.1 (-1.23%)

CRDF Cardiff Oncology
$3.70 /

-0.18 (-4.65%)

BMY Bristol-Myers
$63.56 /

-1.045 (-1.62%)

BAYRY Bayer
$14.62 /

-0.26 (-1.75%)

AZN AstraZeneca
$59.10 /

-1.1 (-1.83%)

AGEN Agenus
$2.70 /

-0.055 (-2.00%)

  • 11
    Nov
  • 22
    Jul
  • 05
    Feb
ZYME Zymeworks
$11.20 /

-0.38 (-3.28%)

PFE Pfizer
$52.78 /

-1.3 (-2.40%)

NVS Novartis
$87.01 /

-1.18 (-1.34%)

NTRA Natera
$62.74 /

-0.355 (-0.56%)

MRK Merck
$79.98 /

-0.765 (-0.95%)

LLY Eli Lilly
$243.12 /

-0.01 (-0.00%)

GH Guardant Health
$70.17 /

-2.36 (-3.25%)

EXAS Exact Sciences
$74.06 /

-2.005 (-2.64%)

ESALY Eisai
$51.92 /

-0.78 (-1.48%)

DNA Ginkgo Bioworks
$5.27 /

+0.165 (+3.23%)

BMY Bristol-Myers
$63.56 /

-1.045 (-1.62%)

BAYRY Bayer
$14.62 /

-0.26 (-1.75%)

AZN AstraZeneca
$59.10 /

-1.1 (-1.83%)

ZYME Zymeworks
$11.20 /

-0.38 (-3.28%)

VCYT Veracyte
$27.00 /

-0.69 (-2.49%)

SGEN Seagen
$127.66 /

-4.85 (-3.66%)

PFE Pfizer
$52.78 /

-1.3 (-2.40%)

NVS Novartis
$87.01 /

-1.18 (-1.34%)

MRTX Mirati Therapeutics
$114.10 /

-4.4 (-3.71%)

MRK Merck
$79.98 /

-0.765 (-0.95%)

LLY Eli Lilly
$243.12 /

-0.01 (-0.00%)

IPSEY Ipsen
$23.66 /

+0.38 (+1.63%)

INCY Incyte
$74.77 /

-0.05 (-0.07%)

GH Guardant Health
$70.17 /

-2.36 (-3.25%)

EXEL Exelixis
$17.34 /

+0.29 (+1.70%)

EXAS Exact Sciences
$74.06 /

-2.005 (-2.64%)

DNA Ginkgo Bioworks
$5.27 /

+0.165 (+3.23%)

DCPH Deciphera
$8.05 /

-0.1 (-1.23%)

CRDF Cardiff Oncology
$3.70 /

-0.18 (-4.65%)

BMY Bristol-Myers
$63.56 /

-1.045 (-1.62%)

BAYRY Bayer
$14.62 /

-0.26 (-1.75%)

AZN AstraZeneca
$59.10 /

-1.1 (-1.83%)

AGEN Agenus
$2.70 /

-0.055 (-2.00%)

PFE Pfizer
$52.78 /

-1.3 (-2.40%)

NVS Novartis
$87.01 /

-1.18 (-1.34%)

MRK Merck
$79.98 /

-0.765 (-0.95%)

LLY Eli Lilly
$243.12 /

-0.01 (-0.00%)

INCY Incyte
$74.77 /

-0.05 (-0.07%)

DNA Ginkgo Bioworks
$5.27 /

+0.165 (+3.23%)

BMY Bristol-Myers
$63.56 /

-1.045 (-1.62%)

AZN AstraZeneca
$59.10 /

-1.1 (-1.83%)

AGEN Agenus
$2.70 /

-0.055 (-2.00%)

Friday
Upgrade
Eli Lilly upgraded to Buy from Hold at DZ Bank » 05:34
01/21/22
01/21
05:34
01/21/22
05:34
LLY

Eli Lilly

$243.13 /

-1.95 (-0.80%)

DZ Bank analyst Elmar…

DZ Bank analyst Elmar Kraus upgraded Eli Lilly to Buy from Hold with a $291 price target.

ShowHide Related Items >><<
LLY Eli Lilly
$243.13 /

-1.95 (-0.80%)

LLY Eli Lilly
$243.13 /

-1.95 (-0.80%)

01/14/22 BofA
Biogen price target lowered to $245 from $275 at BofA
01/12/22 Wells Fargo
CMS proposed coverage with evidence 'a clear negative,' says Wells Fargo
01/05/22 Mizuho
Eli Lilly price target raised to $302 from $272 at Mizuho
01/04/22 Wells Fargo
Eli Lilly price target raised to $280 from $270 at Wells Fargo
LLY Eli Lilly
$243.13 /

-1.95 (-0.80%)

LLY Eli Lilly
$243.13 /

-1.95 (-0.80%)

LLY Eli Lilly
$243.13 /

-1.95 (-0.80%)

LLY Eli Lilly
$243.13 /

-1.95 (-0.80%)

Conference/Events
American Society of Clinical Oncology (ASCO) to hold a symposium » 04:55
01/21/22
01/21
04:55
01/21/22
04:55
AGEN

Agenus

$2.75 /

-0.065 (-2.31%)

, AZN

AstraZeneca

$60.20 /

+0.75 (+1.26%)

, BAYRY

Bayer

$14.88 /

+0.06 (+0.40%)

, BMY

Bristol-Myers

$64.58 /

-0.145 (-0.22%)

, CRDF

Cardiff Oncology

$3.88 /

-0.66 (-14.54%)

, DSNKY

Daiichi Sankyo

$22.69 /

+0.2485 (+1.11%)

, DCPH

Deciphera

$8.15 /

-0.345 (-4.06%)

, DNA

Ginkgo Bioworks

$5.11 /

+0.065 (+1.29%)

, ESALY

Eisai

$52.70 /

+0.53 (+1.02%)

, EXAS

Exact Sciences

$76.14 /

+0.05 (+0.07%)

, EXEL

Exelixis

$17.05 /

-0.04 (-0.23%)

, GH

Guardant Health

$72.74 /

+0.78 (+1.08%)

, HCM

Hutchmed

$30.00 /

+0.32 (+1.08%)

, IMMVF

Immunovia

$7.40 /

+ (+0.00%)

, INCY

Incyte

$74.82 /

+0.03 (+0.04%)

, IPSEY

Ipsen

$23.28 /

-0.8695 (-3.60%)

, LLY

Eli Lilly

$243.13 /

-1.95 (-0.80%)

, MRK

Merck

$80.73 /

-0.57 (-0.70%)

, MRTX

Mirati Therapeutics

$118.50 /

-2.43 (-2.01%)

, NTRA

Natera

$63.19 /

+1.95 (+3.18%)

, NVCR

Novocure

$70.02 /

+5.79 (+9.01%)

, NVS

Novartis

$88.19 /

-0.655 (-0.74%)

, ORIC

Oric Pharmaceuticals

$11.34 /

-0.38 (-3.24%)

, PBLA

Panbela Therapeutics

$1.69 /

+ (+0.00%)

, PFE

Pfizer

$54.05 /

+0.51 (+0.95%)

, SGEN

Seagen

$132.90 /

+0.34 (+0.26%)

, TPTX

Turning Point Therapeutics

$35.87 /

-0.69 (-1.89%)

, VCYT

Veracyte

$27.69 /

+0.46 (+1.69%)

, ZYME

Zymeworks

$11.58 /

-1.86 (-13.84%)

ASCO Gastrointestinal…

ASCO Gastrointestinal Cancers Symposium to be held in San Francisco on January 20-22. Webcast Link

ShowHide Related Items >><<
ZYME Zymeworks
$11.58 /

-1.86 (-13.84%)

VCYT Veracyte
$27.69 /

+0.46 (+1.69%)

TPTX Turning Point Therapeutics
$35.87 /

-0.69 (-1.89%)

SGEN Seagen
$132.90 /

+0.34 (+0.26%)

PFE Pfizer
$54.05 /

+0.51 (+0.95%)

PBLA Panbela Therapeutics
$1.69 /

+ (+0.00%)

ORIC Oric Pharmaceuticals
$11.34 /

-0.38 (-3.24%)

NVS Novartis
$88.19 /

-0.655 (-0.74%)

NVCR Novocure
$70.02 /

+5.79 (+9.01%)

NTRA Natera
$63.19 /

+1.95 (+3.18%)

MRTX Mirati Therapeutics
$118.50 /

-2.43 (-2.01%)

MRK Merck
$80.73 /

-0.57 (-0.70%)

LLY Eli Lilly
$243.13 /

-1.95 (-0.80%)

IPSEY Ipsen
$23.28 /

-0.8695 (-3.60%)

INCY Incyte
$74.82 /

+0.03 (+0.04%)

HCM Hutchmed
$30.00 /

+0.32 (+1.08%)

GH Guardant Health
$72.74 /

+0.78 (+1.08%)

EXEL Exelixis
$17.05 /

-0.04 (-0.23%)

EXAS Exact Sciences
$76.14 /

+0.05 (+0.07%)

ESALY Eisai
$52.70 /

+0.53 (+1.02%)

DSNKY Daiichi Sankyo
$22.69 /

+0.2485 (+1.11%)

DNA Ginkgo Bioworks
$5.11 /

+0.065 (+1.29%)

DCPH Deciphera
$8.15 /

-0.345 (-4.06%)

CRDF Cardiff Oncology
$3.88 /

-0.66 (-14.54%)

BMY Bristol-Myers
$64.58 /

-0.145 (-0.22%)

BAYRY Bayer
$14.88 /

+0.06 (+0.40%)

AZN AstraZeneca
$60.20 /

+0.75 (+1.26%)

AGEN Agenus
$2.75 /

-0.065 (-2.31%)

AGEN Agenus
$2.75 /

-0.065 (-2.31%)

12/16/21 H.C. Wainwright
Agenus initiated with a Buy at H.C. Wainwright
12/06/21 B. Riley
B. Riley bullish on Novavax, Agenus amid Omicron spread
11/09/21 Evercore ISI
Evercore starts Agenus spinout MiNK Therapeutics with an Outperform
10/25/21 B. Riley
Agenus price target lowered to $11 from $12 at B. Riley
AZN AstraZeneca
$60.20 /

+0.75 (+1.26%)

12/30/21 SVB Leerink
SVB Leerink confident Adbry poses minimal competitive risk to Dupixent
12/16/21 Morgan Stanley
AstraZeneca price target raised to 10,200 GBp from 10,000 GBp at Morgan Stanley
12/16/21 Stifel
Adagio story 'even more complicated' after preprints on ADG20, says Stifel
12/12/21 Piper Sandler
Schrodinger MALT1 preclinical data supports IND filing in 1H22, says Piper
BAYRY Bayer
$14.88 /

+0.06 (+0.40%)

11/15/21 AlphaValue/Baader
Bayer upgraded to Buy from Add at AlphaValue/Baader
11/10/21 JPMorgan
Bayer price target raised to EUR 75 from EUR 67 at JPMorgan
11/10/21 Morgan Stanley
Bayer price target raised to EUR 74 from EUR 71 at Morgan Stanley
11/10/21 Credit Suisse
Bayer price target raised to EUR 57 from EUR 55 at Credit Suisse
BMY Bristol-Myers
$64.58 /

-0.145 (-0.22%)

01/10/22 Piper Sandler
Piper says Century Therapeutics' alliance with Bristol 'transformational'
01/03/22 Piper Sandler
Legend Biotech named a top pick for 2022 at Piper Sandler
12/21/21 Oppenheimer
Oppenheimer starts Cytokinetics at Outperform, sees 'blockbuster' potential
12/21/21 Piper Sandler
Legend Biotech initiated with an Overweight at Piper Sandler
CRDF Cardiff Oncology
$3.88 /

-0.66 (-14.54%)

12/07/21 Baird
Cardiff Oncology initiated with an Outperform at Baird
11/18/21 Piper Sandler
Cardiff investment by Pfizer 'some nice validation,' says Piper Sandler
09/09/21 Maxim
Cardiff Oncology price target raised to $25 from $20 at Maxim
09/09/21 Piper Sandler
Cardiff colorectal cancer data 'very consistent,' says Piper Sandler
DSNKY Daiichi Sankyo
$22.69 /

+0.2485 (+1.11%)

10/27/21 SVB Leerink
Seagen price target raised to $200 from $190 at SVB Leerink
03/15/21 Citi
Citi opens 'positive catalyst watch' on Daiichi Sankyo
03/08/21 Goldman Sachs
Daiichi Sankyo upgraded to Buy from Neutral at Goldman Sachs
DCPH Deciphera
$8.15 /

-0.345 (-4.06%)

12/01/21 H.C. Wainwright
Deciphera price target lowered to $15 from $25 at H.C. Wainwright
11/30/21 Piper Sandler
Deciphera price target lowered to $11 from $14 at Piper Sandler
11/08/21 Barclays
Deciphera downgraded to Equal Weight at Barclays after GIST trial miss
11/08/21 Canaccord
Deciphera downgraded to Hold at Canaccord
DNA Ginkgo Bioworks
$5.11 /

+0.065 (+1.29%)

01/06/22 BTIG
BTIG starts Ginkgo Bioworks at Buy with $12 price target
01/06/22 BTIG
Ginkgo Bioworks initiated with a Buy at BTIG
11/29/21 Jefferies
Ginkgo Bioworks initiated with a Buy at Jefferies
10/20/21 Raymond James
Raymond James expects more equity-based payments for Ginkgo as milestones met
ESALY Eisai
$52.70 /

+0.53 (+1.02%)

01/13/22 Citi
Eisai downgraded to Neutral from Buy at Citi
10/08/21 Jefferies
Biogen price target lowered to $400 from $500 at Jefferies
09/30/21 RBC Capital
Prothena price target raised to $82 from $59 at RBC Capital
06/25/21 Morgan Stanley
Eisai downgraded to Equal Weight from Overweight at Morgan Stanley
EXAS Exact Sciences
$76.14 /

+0.05 (+0.07%)

11/03/21 BTIG
Exact Sciences price target lowered to $120 from $145 at BTIG
11/03/21 Craig-Hallum
Exact Sciences price target lowered to $133 from $144 at Craig-Hallum
11/03/21 Raymond James
Exact Sciences downgraded to Outperform from Strong Buy at Raymond James
11/03/21 Wells Fargo
Exact Sciences price target lowered to $95 from $120 at Wells Fargo
EXEL Exelixis
$17.05 /

-0.04 (-0.23%)

11/18/21 Piper Sandler
Exelixis transferred with Overweight at Piper Sandler
11/03/21 H.C. Wainwright
Exelixis price target lowered to $52 from $65 at H.C. Wainwright
10/06/21 Jefferies
Exelixis initiated with a Buy at Jefferies
08/06/21 H.C. Wainwright
Exelixis price target raised to $64 from $35 at H.C. Wainwright
GH Guardant Health
$72.74 /

+0.78 (+1.08%)

10/14/21 Cowen
Guardant Health coverage transferred at Cowen
08/09/21 Canaccord
Guardant Health price target lowered to $180 from $195 at Canaccord
06/21/21 Wells Fargo
Guardant Health price target raised to $160 from $145 at Wells Fargo
06/15/21
Fly Intel: Top five analyst initiations
HCM Hutchmed
$30.00 /

+0.32 (+1.08%)

09/22/21
Fly Intel: Top five analyst downgrades
09/22/21 Goldman Sachs
Hutchmed downgraded to Neutral from Buy at Goldman Sachs
08/03/21 Jefferies
Hutchmed initiated with a Buy at Jefferies
07/13/21 Cantor Fitzgerald
Hutchmed price target raised to $45 from $40 at Cantor Fitzgerald
IMMVF Immunovia
$7.40 /

+ (+0.00%)

12/22/21 Kempen
Immunovia downgraded to Neutral from Buy at Kempen
INCY Incyte
$74.82 /

+0.03 (+0.04%)

01/18/22 RBC Capital
Incyte upgraded to Outperform at RBC Capital on improving 2022 setup
01/18/22 RBC Capital
Incyte upgraded to Outperform from Sector Perform at RBC Capital
01/03/22 Guggenheim
Incyte price target lowered to $104 from $118 at Guggenheim
12/31/21 Benchmark
Incyte, Nektar, Compass Therapeutics named best biotech picks at Benchmark
IPSEY Ipsen
$23.28 /

-0.8695 (-3.60%)

01/11/22 Bryan Garnier
Ipsen upgraded to Buy from Neutral at Bryan Garnier
01/06/22 Societe Generale
Ipsen upgraded to Buy from Hold at Societe Generale
01/04/22 JPMorgan
Ipsen downgraded to Neutral from Overweight at JPMorgan
11/24/21 Berenberg
Ipsen initiated with a Hold at Berenberg
LLY Eli Lilly
$243.13 /

-1.95 (-0.80%)

01/14/22 BofA
Biogen price target lowered to $245 from $275 at BofA
01/12/22 Wells Fargo
CMS proposed coverage with evidence 'a clear negative,' says Wells Fargo
01/05/22 Mizuho
Eli Lilly price target raised to $302 from $272 at Mizuho
01/04/22 Wells Fargo
Eli Lilly price target raised to $280 from $270 at Wells Fargo
MRK Merck
$80.73 /

-0.57 (-0.70%)

12/23/21 Mizuho
Mizuho sees market for both Merck's molnupiravir, Pfizer's Paxlovid
12/17/21 Goldman Sachs
Goldman starts Merck at Conviction Buy with market undervaluing assets
12/17/21 Goldman Sachs
Merck initiated with a Conviction Buy at Goldman Sachs
12/16/21 Daiwa
Merck initiated with a Neutral at Daiwa
MRTX Mirati Therapeutics
$118.50 /

-2.43 (-2.01%)

11/18/21 BMO Capital
Amgen initiated with a Market Perform at BMO Capital
11/18/21 BMO Capital
Mirati Therapeutics initiated with an Outperform at BMO Capital
09/22/21 Stifel
Mirati Therapeutics initiated with a Buy at Stifel
09/22/21 Citi
Mirati Therapeutics price target raised to $244 from $232 at Citi
NTRA Natera
$63.19 /

+1.95 (+3.18%)

01/12/22 BTIG
Natera price target lowered to $150, named one of top 2022 picks at BTIG
01/05/22 Piper Sandler
Natera assumed with an Overweight at Piper Sandler
01/04/22 Canaccord
Natera weakness a buying opportunity, says Canaccord
11/05/21 Baird
Natera price target raised to $152 from $145 at Baird
NVCR Novocure
$70.02 /

+5.79 (+9.01%)

01/20/22 Truist
Novocure upgraded to Buy on more favorable risk-reward at Truist
01/20/22 Truist
Novocure upgraded to Buy from Hold at Truist
01/11/22 Wells Fargo
Novocure price target lowered to $70 from $105 at Wells Fargo
01/10/22 Piper Sandler
Novocure price target lowered to $125 from $130 at Piper Sandler
NVS Novartis
$88.19 /

-0.655 (-0.74%)

01/12/22 Alliance Global Partners
OpGen price target lowered to $3 from $4.35 at Alliance Global Partners
01/10/22 Citi
Novartis resumed with a Buy at Citi
01/06/22 Piper Sandler
Piper want to own Alnylam shares ahead of expected vutrisiran approval
12/15/21 Berenberg
Novartis price target lowered to CHF 85 from CHF 88 at Berenberg
ORIC Oric Pharmaceuticals
$11.34 /

-0.38 (-3.24%)

10/08/21 Baird
Oric Pharmaceuticals price target lowered to $26 from $47 at Baird
10/08/21 Citi
Oric Pharmaceuticals price target lowered to $22 from $33 at Citi
10/08/21 H.C. Wainwright
Oric Pharmaceuticals price target lowered to $30 from $53 at H.C. Wainwright
10/07/21 Oppenheimer
Oppenheimer remains bullish on Oric Pharmaceuticals, says selloff 'overdone'
PBLA Panbela Therapeutics
$1.69 /

+ (+0.00%)

06/28/21 Roth Capital
Panbela Therapeutics initiated with a Buy at Roth Capital
03/10/21 Maxim
Panbela Therapeutics initiated with a Buy at Maxim
PFE Pfizer
$54.05 /

+0.51 (+0.95%)

01/14/22 BMO Capital
Pfizer price target raised to $76 from $60 at BMO Capital
01/11/22 BofA
Pfizer added to US 1 List; Goldman Sachs removed at BofA
01/10/22 Wedbush
Beam Therapeutics price target raised to $159 from $148 at Wedbush
01/05/22 BofA
Pfizer upgraded to Buy from Neutral at BofA
SGEN Seagen
$132.90 /

+0.34 (+0.26%)

11/08/21 Wolfe Research
Seagen initiated with a Peer Perform at Wolfe Research
10/28/21 Piper Sandler
Seagen price target raised to $165 from $160 at Piper Sandler
10/28/21 Piper Sandler
Seagen price target raised to $165 from $160 at Piper Sandler
TPTX Turning Point Therapeutics
$35.87 /

-0.69 (-1.89%)

01/03/22 Guggenheim
Turning Point Therapeutics price target lowered to $107 from $118 at Guggenheim
12/22/21 Roth Capital
Turning Point FDA feedback appears positive, says Roth Capital
12/06/21 Cowen
Turning Point Therapeutics initiated with an Outperform at Cowen
11/15/21 Roth Capital
Turning Point fundamentals strong heading into 2022, says Roth Capital
VCYT Veracyte
$27.69 /

+0.46 (+1.69%)

01/06/22 Stephens
Veracyte initiated with Overweight, named best idea at Stephens
11/18/21 Goldman Sachs
Veracyte reinstated with a Buy at Goldman Sachs
11/10/21 Raymond James
Veracyte price target raised to $62 from $50 at Raymond James
06/28/21 Raymond James
Veracyte price target raised to $50 from $45 at Raymond James
ZYME Zymeworks
$11.58 /

-1.86 (-13.84%)

12/10/21 Raymond James
Zymeworks downgraded to Outperform from Strong Buy at Raymond James
12/10/21 SVB Leerink
Zymeworks upgraded to Outperform from Market Perform at SVB Leerink
12/09/21 Raymond James
Zymeworks downgraded to Outperform from Strong Buy at Raymond James
11/17/21 Guggenheim
Zymeworks assumed with a Neutral at Guggenheim
ZYME Zymeworks
$11.58 /

-1.86 (-13.84%)

VCYT Veracyte
$27.69 /

+0.46 (+1.69%)

TPTX Turning Point Therapeutics
$35.87 /

-0.69 (-1.89%)

SGEN Seagen
$132.90 /

+0.34 (+0.26%)

PFE Pfizer
$54.05 /

+0.51 (+0.95%)

PBLA Panbela Therapeutics
$1.69 /

+ (+0.00%)

ORIC Oric Pharmaceuticals
$11.34 /

-0.38 (-3.24%)

NVS Novartis
$88.19 /

-0.655 (-0.74%)

NVCR Novocure
$70.02 /

+5.79 (+9.01%)

NTRA Natera
$63.19 /

+1.95 (+3.18%)

MRTX Mirati Therapeutics
$118.50 /

-2.43 (-2.01%)

MRK Merck
$80.73 /

-0.57 (-0.70%)

LLY Eli Lilly
$243.13 /

-1.95 (-0.80%)

INCY Incyte
$74.82 /

+0.03 (+0.04%)

GH Guardant Health
$72.74 /

+0.78 (+1.08%)

EXEL Exelixis
$17.05 /

-0.04 (-0.23%)

EXAS Exact Sciences
$76.14 /

+0.05 (+0.07%)

DNA Ginkgo Bioworks
$5.11 /

+0.065 (+1.29%)

DCPH Deciphera
$8.15 /

-0.345 (-4.06%)

CRDF Cardiff Oncology
$3.88 /

-0.66 (-14.54%)

BMY Bristol-Myers
$64.58 /

-0.145 (-0.22%)

BAYRY Bayer
$14.88 /

+0.06 (+0.40%)

AZN AstraZeneca
$60.20 /

+0.75 (+1.26%)

AGEN Agenus
$2.75 /

-0.065 (-2.31%)

  • 11
    Nov
  • 22
    Jul
  • 05
    Feb
ZYME Zymeworks
$11.58 /

-1.86 (-13.84%)

PFE Pfizer
$54.05 /

+0.51 (+0.95%)

NVS Novartis
$88.19 /

-0.655 (-0.74%)

NTRA Natera
$63.19 /

+1.95 (+3.18%)

MRK Merck
$80.73 /

-0.57 (-0.70%)

LLY Eli Lilly
$243.13 /

-1.95 (-0.80%)

GH Guardant Health
$72.74 /

+0.78 (+1.08%)

EXAS Exact Sciences
$76.14 /

+0.05 (+0.07%)

ESALY Eisai
$52.70 /

+0.53 (+1.02%)

DNA Ginkgo Bioworks
$5.11 /

+0.065 (+1.29%)

BMY Bristol-Myers
$64.58 /

-0.145 (-0.22%)

BAYRY Bayer
$14.88 /

+0.06 (+0.40%)

AZN AstraZeneca
$60.20 /

+0.75 (+1.26%)

ZYME Zymeworks
$11.58 /

-1.86 (-13.84%)

VCYT Veracyte
$27.69 /

+0.46 (+1.69%)

SGEN Seagen
$132.90 /

+0.34 (+0.26%)

PFE Pfizer
$54.05 /

+0.51 (+0.95%)

NVS Novartis
$88.19 /

-0.655 (-0.74%)

MRTX Mirati Therapeutics
$118.50 /

-2.43 (-2.01%)

MRK Merck
$80.73 /

-0.57 (-0.70%)

LLY Eli Lilly
$243.13 /

-1.95 (-0.80%)

IPSEY Ipsen
$23.28 /

-0.8695 (-3.60%)

INCY Incyte
$74.82 /

+0.03 (+0.04%)

GH Guardant Health
$72.74 /

+0.78 (+1.08%)

EXEL Exelixis
$17.05 /

-0.04 (-0.23%)

EXAS Exact Sciences
$76.14 /

+0.05 (+0.07%)

DNA Ginkgo Bioworks
$5.11 /

+0.065 (+1.29%)

DCPH Deciphera
$8.15 /

-0.345 (-4.06%)

CRDF Cardiff Oncology
$3.88 /

-0.66 (-14.54%)

BMY Bristol-Myers
$64.58 /

-0.145 (-0.22%)

BAYRY Bayer
$14.88 /

+0.06 (+0.40%)

AZN AstraZeneca
$60.20 /

+0.75 (+1.26%)

AGEN Agenus
$2.75 /

-0.065 (-2.31%)

PFE Pfizer
$54.05 /

+0.51 (+0.95%)

NVS Novartis
$88.19 /

-0.655 (-0.74%)

MRK Merck
$80.73 /

-0.57 (-0.70%)

LLY Eli Lilly
$243.13 /

-1.95 (-0.80%)

INCY Incyte
$74.82 /

+0.03 (+0.04%)

DNA Ginkgo Bioworks
$5.11 /

+0.065 (+1.29%)

BMY Bristol-Myers
$64.58 /

-0.145 (-0.22%)

AZN AstraZeneca
$60.20 /

+0.75 (+1.26%)

AGEN Agenus
$2.75 /

-0.065 (-2.31%)

Thursday
Conference/Events
American Society of Clinical Oncology (ASCO) to hold a symposium » 09:34
01/20/22
01/20
09:34
01/20/22
09:34
AGEN

Agenus

$2.82 /

-0.035 (-1.23%)

, AZN

AstraZeneca

$59.46 /

-0.37 (-0.62%)

, BAYRY

Bayer

$14.82 /

+0.13 (+0.88%)

, BMY

Bristol-Myers

$64.73 /

-0.175 (-0.27%)

, CRDF

Cardiff Oncology

$4.54 /

-1.585 (-25.88%)

, DSNKY

Daiichi Sankyo

$22.44 /

-0.5385 (-2.34%)

, DCPH

Deciphera

$8.50 /

+0.225 (+2.72%)

, DNA

Ginkgo Bioworks

$5.04 /

-0.25 (-4.73%)

, ESALY

Eisai

$52.17 /

-0.39 (-0.74%)

, EXAS

Exact Sciences

$76.09 /

-1.24 (-1.60%)

, EXEL

Exelixis

$17.09 /

-0.28 (-1.61%)

, GH

Guardant Health

$71.99 /

-0.48 (-0.66%)

, HCM

Hutchmed

$29.71 /

-0.76 (-2.49%)

, IMMVF

Immunovia

$7.40 /

+ (+0.00%)

, INCY

Incyte

$74.81 /

-0.19 (-0.25%)

, IPSEY

Ipsen

$24.15 /

+0.4145 (+1.75%)

, LLY

Eli Lilly

$245.08 /

-2.075 (-0.84%)

, MRK

Merck

$81.30 /

-0.25 (-0.31%)

, MRTX

Mirati Therapeutics

$120.93 /

+4.85 (+4.18%)

, NTRA

Natera

$61.27 /

+0.14 (+0.23%)

, NVCR

Novocure

$64.11 /

-0.37 (-0.57%)

, NVS

Novartis

$88.85 /

-0.7 (-0.78%)

, ORIC

Oric Pharmaceuticals

$11.72 /

-0.13 (-1.10%)

, PBLA

Panbela Therapeutics

$1.68 /

-0.06 (-3.45%)

, PFE

Pfizer

$53.54 /

-0.58 (-1.07%)

, SGEN

Seagen

$132.55 /

+2.2 (+1.69%)

, TPTX

Turning Point Therapeutics

$36.57 /

+0.44 (+1.22%)

, VCYT

Veracyte

$27.23 /

-0.54 (-1.94%)

, ZYME

Zymeworks

$13.44 /

+0.055 (+0.41%)

ASCO Gastrointestinal…

ASCO Gastrointestinal Cancers Symposium to be held in San Francisco on January 20-22. Webcast Link

ShowHide Related Items >><<
ZYME Zymeworks
$13.44 /

+0.055 (+0.41%)

VCYT Veracyte
$27.23 /

-0.54 (-1.94%)

TPTX Turning Point Therapeutics
$36.57 /

+0.44 (+1.22%)

SGEN Seagen
$132.55 /

+2.2 (+1.69%)

PFE Pfizer
$53.54 /

-0.58 (-1.07%)

PBLA Panbela Therapeutics
$1.68 /

-0.06 (-3.45%)

ORIC Oric Pharmaceuticals
$11.72 /

-0.13 (-1.10%)

NVS Novartis
$88.85 /

-0.7 (-0.78%)

NVCR Novocure
$64.11 /

-0.37 (-0.57%)

NTRA Natera
$61.27 /

+0.14 (+0.23%)

MRTX Mirati Therapeutics
$120.93 /

+4.85 (+4.18%)

MRK Merck
$81.30 /

-0.25 (-0.31%)

LLY Eli Lilly
$245.08 /

-2.075 (-0.84%)

IPSEY Ipsen
$24.15 /

+0.4145 (+1.75%)

INCY Incyte
$74.81 /

-0.19 (-0.25%)

HCM Hutchmed
$29.71 /

-0.76 (-2.49%)

GH Guardant Health
$71.99 /

-0.48 (-0.66%)

EXEL Exelixis
$17.09 /

-0.28 (-1.61%)

EXAS Exact Sciences
$76.09 /

-1.24 (-1.60%)

ESALY Eisai
$52.17 /

-0.39 (-0.74%)

DSNKY Daiichi Sankyo
$22.44 /

-0.5385 (-2.34%)

DNA Ginkgo Bioworks
$5.04 /

-0.25 (-4.73%)

DCPH Deciphera
$8.50 /

+0.225 (+2.72%)

CRDF Cardiff Oncology
$4.54 /

-1.585 (-25.88%)

BMY Bristol-Myers
$64.73 /

-0.175 (-0.27%)

BAYRY Bayer
$14.82 /

+0.13 (+0.88%)

AZN AstraZeneca
$59.46 /

-0.37 (-0.62%)

AGEN Agenus
$2.82 /

-0.035 (-1.23%)

AGEN Agenus
$2.82 /

-0.035 (-1.23%)

12/16/21 H.C. Wainwright
Agenus initiated with a Buy at H.C. Wainwright
12/06/21 B. Riley
B. Riley bullish on Novavax, Agenus amid Omicron spread
11/09/21 Evercore ISI
Evercore starts Agenus spinout MiNK Therapeutics with an Outperform
10/25/21 B. Riley
Agenus price target lowered to $11 from $12 at B. Riley
AZN AstraZeneca
$59.46 /

-0.37 (-0.62%)

12/30/21 SVB Leerink
SVB Leerink confident Adbry poses minimal competitive risk to Dupixent
12/16/21 Morgan Stanley
AstraZeneca price target raised to 10,200 GBp from 10,000 GBp at Morgan Stanley
12/16/21 Stifel
Adagio story 'even more complicated' after preprints on ADG20, says Stifel
12/12/21 Piper Sandler
Schrodinger MALT1 preclinical data supports IND filing in 1H22, says Piper
BAYRY Bayer
$14.82 /

+0.13 (+0.88%)

11/15/21 AlphaValue/Baader
Bayer upgraded to Buy from Add at AlphaValue/Baader
11/10/21 JPMorgan
Bayer price target raised to EUR 75 from EUR 67 at JPMorgan
11/10/21 Morgan Stanley
Bayer price target raised to EUR 74 from EUR 71 at Morgan Stanley
11/10/21 Credit Suisse
Bayer price target raised to EUR 57 from EUR 55 at Credit Suisse
BMY Bristol-Myers
$64.73 /

-0.175 (-0.27%)

01/10/22 Piper Sandler
Piper says Century Therapeutics' alliance with Bristol 'transformational'
01/03/22 Piper Sandler
Legend Biotech named a top pick for 2022 at Piper Sandler
12/21/21 Oppenheimer
Oppenheimer starts Cytokinetics at Outperform, sees 'blockbuster' potential
12/21/21 Piper Sandler
Legend Biotech initiated with an Overweight at Piper Sandler
CRDF Cardiff Oncology
$4.54 /

-1.585 (-25.88%)

12/07/21 Baird
Cardiff Oncology initiated with an Outperform at Baird
11/18/21 Piper Sandler
Cardiff investment by Pfizer 'some nice validation,' says Piper Sandler
09/09/21 Maxim
Cardiff Oncology price target raised to $25 from $20 at Maxim
09/09/21 Piper Sandler
Cardiff colorectal cancer data 'very consistent,' says Piper Sandler
DSNKY Daiichi Sankyo
$22.44 /

-0.5385 (-2.34%)

10/27/21 SVB Leerink
Seagen price target raised to $200 from $190 at SVB Leerink
03/15/21 Citi
Citi opens 'positive catalyst watch' on Daiichi Sankyo
03/08/21 Goldman Sachs
Daiichi Sankyo upgraded to Buy from Neutral at Goldman Sachs
DCPH Deciphera
$8.50 /

+0.225 (+2.72%)

12/01/21 H.C. Wainwright
Deciphera price target lowered to $15 from $25 at H.C. Wainwright
11/30/21 Piper Sandler
Deciphera price target lowered to $11 from $14 at Piper Sandler
11/08/21 Barclays
Deciphera downgraded to Equal Weight at Barclays after GIST trial miss
11/08/21 Canaccord
Deciphera downgraded to Hold at Canaccord
DNA Ginkgo Bioworks
$5.04 /

-0.25 (-4.73%)

01/06/22 BTIG
BTIG starts Ginkgo Bioworks at Buy with $12 price target
01/06/22 BTIG
Ginkgo Bioworks initiated with a Buy at BTIG
11/29/21 Jefferies
Ginkgo Bioworks initiated with a Buy at Jefferies
10/20/21 Raymond James
Raymond James expects more equity-based payments for Ginkgo as milestones met
ESALY Eisai
$52.17 /

-0.39 (-0.74%)

01/13/22 Citi
Eisai downgraded to Neutral from Buy at Citi
10/08/21 Jefferies
Biogen price target lowered to $400 from $500 at Jefferies
09/30/21 RBC Capital
Prothena price target raised to $82 from $59 at RBC Capital
06/25/21 Morgan Stanley
Eisai downgraded to Equal Weight from Overweight at Morgan Stanley
EXAS Exact Sciences
$76.09 /

-1.24 (-1.60%)

11/03/21 BTIG
Exact Sciences price target lowered to $120 from $145 at BTIG
11/03/21 Craig-Hallum
Exact Sciences price target lowered to $133 from $144 at Craig-Hallum
11/03/21 Raymond James
Exact Sciences downgraded to Outperform from Strong Buy at Raymond James
11/03/21 Wells Fargo
Exact Sciences price target lowered to $95 from $120 at Wells Fargo
EXEL Exelixis
$17.09 /

-0.28 (-1.61%)

11/18/21 Piper Sandler
Exelixis transferred with Overweight at Piper Sandler
11/03/21 H.C. Wainwright
Exelixis price target lowered to $52 from $65 at H.C. Wainwright
10/06/21 Jefferies
Exelixis initiated with a Buy at Jefferies
08/06/21 H.C. Wainwright
Exelixis price target raised to $64 from $35 at H.C. Wainwright
GH Guardant Health
$71.99 /

-0.48 (-0.66%)

10/14/21 Cowen
Guardant Health coverage transferred at Cowen
08/09/21 Canaccord
Guardant Health price target lowered to $180 from $195 at Canaccord
06/21/21 Wells Fargo
Guardant Health price target raised to $160 from $145 at Wells Fargo
06/15/21
Fly Intel: Top five analyst initiations
HCM Hutchmed
$29.71 /

-0.76 (-2.49%)

09/22/21
Fly Intel: Top five analyst downgrades
09/22/21 Goldman Sachs
Hutchmed downgraded to Neutral from Buy at Goldman Sachs
08/03/21 Jefferies
Hutchmed initiated with a Buy at Jefferies
07/13/21 Cantor Fitzgerald
Hutchmed price target raised to $45 from $40 at Cantor Fitzgerald
IMMVF Immunovia
$7.40 /

+ (+0.00%)

12/22/21 Kempen
Immunovia downgraded to Neutral from Buy at Kempen
INCY Incyte
$74.81 /

-0.19 (-0.25%)

01/18/22 RBC Capital
Incyte upgraded to Outperform at RBC Capital on improving 2022 setup
01/18/22 RBC Capital
Incyte upgraded to Outperform from Sector Perform at RBC Capital
01/03/22 Guggenheim
Incyte price target lowered to $104 from $118 at Guggenheim
12/31/21 Benchmark
Incyte, Nektar, Compass Therapeutics named best biotech picks at Benchmark
IPSEY Ipsen
$24.15 /

+0.4145 (+1.75%)

01/11/22 Bryan Garnier
Ipsen upgraded to Buy from Neutral at Bryan Garnier
01/06/22 Societe Generale
Ipsen upgraded to Buy from Hold at Societe Generale
01/04/22 JPMorgan
Ipsen downgraded to Neutral from Overweight at JPMorgan
11/24/21 Berenberg
Ipsen initiated with a Hold at Berenberg
LLY Eli Lilly
$245.08 /

-2.075 (-0.84%)

01/14/22 BofA
Biogen price target lowered to $245 from $275 at BofA
01/12/22 Wells Fargo
CMS proposed coverage with evidence 'a clear negative,' says Wells Fargo
01/05/22 Mizuho
Eli Lilly price target raised to $302 from $272 at Mizuho
01/04/22 Wells Fargo
Eli Lilly price target raised to $280 from $270 at Wells Fargo
MRK Merck
$81.30 /

-0.25 (-0.31%)

12/23/21 Mizuho
Mizuho sees market for both Merck's molnupiravir, Pfizer's Paxlovid
12/17/21 Goldman Sachs
Goldman starts Merck at Conviction Buy with market undervaluing assets
12/17/21 Goldman Sachs
Merck initiated with a Conviction Buy at Goldman Sachs
12/16/21 Daiwa
Merck initiated with a Neutral at Daiwa
MRTX Mirati Therapeutics
$120.93 /

+4.85 (+4.18%)

11/18/21 BMO Capital
Amgen initiated with a Market Perform at BMO Capital
11/18/21 BMO Capital
Mirati Therapeutics initiated with an Outperform at BMO Capital
09/22/21 Stifel
Mirati Therapeutics initiated with a Buy at Stifel
09/22/21 Citi
Mirati Therapeutics price target raised to $244 from $232 at Citi
NTRA Natera
$61.27 /

+0.14 (+0.23%)

01/12/22 BTIG
Natera price target lowered to $150, named one of top 2022 picks at BTIG
01/05/22 Piper Sandler
Natera assumed with an Overweight at Piper Sandler
01/04/22 Canaccord
Natera weakness a buying opportunity, says Canaccord
11/05/21 Baird
Natera price target raised to $152 from $145 at Baird
NVCR Novocure
$64.11 /

-0.37 (-0.57%)

01/20/22 Truist
Novocure upgraded to Buy on more favorable risk-reward at Truist
01/20/22 Truist
Novocure upgraded to Buy from Hold at Truist
01/11/22 Wells Fargo
Novocure price target lowered to $70 from $105 at Wells Fargo
01/10/22 Piper Sandler
Novocure price target lowered to $125 from $130 at Piper Sandler
NVS Novartis
$88.85 /

-0.7 (-0.78%)

01/12/22 Alliance Global Partners
OpGen price target lowered to $3 from $4.35 at Alliance Global Partners
01/10/22 Citi
Novartis resumed with a Buy at Citi
01/06/22 Piper Sandler
Piper want to own Alnylam shares ahead of expected vutrisiran approval
12/15/21 Berenberg
Novartis price target lowered to CHF 85 from CHF 88 at Berenberg
ORIC Oric Pharmaceuticals
$11.72 /

-0.13 (-1.10%)

10/08/21 Baird
Oric Pharmaceuticals price target lowered to $26 from $47 at Baird
10/08/21 Citi
Oric Pharmaceuticals price target lowered to $22 from $33 at Citi
10/08/21 H.C. Wainwright
Oric Pharmaceuticals price target lowered to $30 from $53 at H.C. Wainwright
10/07/21 Oppenheimer
Oppenheimer remains bullish on Oric Pharmaceuticals, says selloff 'overdone'
PBLA Panbela Therapeutics
$1.68 /

-0.06 (-3.45%)

06/28/21 Roth Capital
Panbela Therapeutics initiated with a Buy at Roth Capital
03/10/21 Maxim
Panbela Therapeutics initiated with a Buy at Maxim
PFE Pfizer
$53.54 /

-0.58 (-1.07%)

01/14/22 BMO Capital
Pfizer price target raised to $76 from $60 at BMO Capital
01/11/22 BofA
Pfizer added to US 1 List; Goldman Sachs removed at BofA
01/10/22 Wedbush
Beam Therapeutics price target raised to $159 from $148 at Wedbush
01/05/22 BofA
Pfizer upgraded to Buy from Neutral at BofA
SGEN Seagen
$132.55 /

+2.2 (+1.69%)

11/08/21 Wolfe Research
Seagen initiated with a Peer Perform at Wolfe Research
10/28/21 Piper Sandler
Seagen price target raised to $165 from $160 at Piper Sandler
10/28/21 Piper Sandler
Seagen price target raised to $165 from $160 at Piper Sandler
TPTX Turning Point Therapeutics
$36.57 /

+0.44 (+1.22%)

01/03/22 Guggenheim
Turning Point Therapeutics price target lowered to $107 from $118 at Guggenheim
12/22/21 Roth Capital
Turning Point FDA feedback appears positive, says Roth Capital
12/06/21 Cowen
Turning Point Therapeutics initiated with an Outperform at Cowen
11/15/21 Roth Capital
Turning Point fundamentals strong heading into 2022, says Roth Capital
VCYT Veracyte
$27.23 /

-0.54 (-1.94%)

01/06/22 Stephens
Veracyte initiated with Overweight, named best idea at Stephens
11/18/21 Goldman Sachs
Veracyte reinstated with a Buy at Goldman Sachs
11/10/21 Raymond James
Veracyte price target raised to $62 from $50 at Raymond James
06/28/21 Raymond James
Veracyte price target raised to $50 from $45 at Raymond James
ZYME Zymeworks
$13.44 /

+0.055 (+0.41%)

12/10/21 Raymond James
Zymeworks downgraded to Outperform from Strong Buy at Raymond James
12/10/21 SVB Leerink
Zymeworks upgraded to Outperform from Market Perform at SVB Leerink
12/09/21 Raymond James
Zymeworks downgraded to Outperform from Strong Buy at Raymond James
11/17/21 Guggenheim
Zymeworks assumed with a Neutral at Guggenheim
ZYME Zymeworks
$13.44 /

+0.055 (+0.41%)

VCYT Veracyte
$27.23 /

-0.54 (-1.94%)

TPTX Turning Point Therapeutics
$36.57 /

+0.44 (+1.22%)

SGEN Seagen
$132.55 /

+2.2 (+1.69%)

PFE Pfizer
$53.54 /

-0.58 (-1.07%)

PBLA Panbela Therapeutics
$1.68 /

-0.06 (-3.45%)

ORIC Oric Pharmaceuticals
$11.72 /

-0.13 (-1.10%)

NVS Novartis
$88.85 /

-0.7 (-0.78%)

NVCR Novocure
$64.11 /

-0.37 (-0.57%)

NTRA Natera
$61.27 /

+0.14 (+0.23%)

MRTX Mirati Therapeutics
$120.93 /

+4.85 (+4.18%)

MRK Merck
$81.30 /

-0.25 (-0.31%)

LLY Eli Lilly
$245.08 /

-2.075 (-0.84%)

INCY Incyte
$74.81 /

-0.19 (-0.25%)

GH Guardant Health
$71.99 /

-0.48 (-0.66%)

EXEL Exelixis
$17.09 /

-0.28 (-1.61%)

EXAS Exact Sciences
$76.09 /

-1.24 (-1.60%)

DNA Ginkgo Bioworks
$5.04 /

-0.25 (-4.73%)

DCPH Deciphera
$8.50 /

+0.225 (+2.72%)

CRDF Cardiff Oncology
$4.54 /

-1.585 (-25.88%)

BMY Bristol-Myers
$64.73 /

-0.175 (-0.27%)

BAYRY Bayer
$14.82 /

+0.13 (+0.88%)

AZN AstraZeneca
$59.46 /

-0.37 (-0.62%)

AGEN Agenus
$2.82 /

-0.035 (-1.23%)

  • 11
    Nov
  • 22
    Jul
  • 05
    Feb
ZYME Zymeworks
$13.44 /

+0.055 (+0.41%)

PFE Pfizer
$53.54 /

-0.58 (-1.07%)

NVS Novartis
$88.85 /

-0.7 (-0.78%)

NTRA Natera
$61.27 /

+0.14 (+0.23%)

MRK Merck
$81.30 /

-0.25 (-0.31%)

LLY Eli Lilly
$245.08 /

-2.075 (-0.84%)

GH Guardant Health
$71.99 /

-0.48 (-0.66%)

EXAS Exact Sciences
$76.09 /

-1.24 (-1.60%)

ESALY Eisai
$52.17 /

-0.39 (-0.74%)

DNA Ginkgo Bioworks
$5.04 /

-0.25 (-4.73%)

BMY Bristol-Myers
$64.73 /

-0.175 (-0.27%)

BAYRY Bayer
$14.82 /

+0.13 (+0.88%)

AZN AstraZeneca
$59.46 /

-0.37 (-0.62%)

ZYME Zymeworks
$13.44 /

+0.055 (+0.41%)

VCYT Veracyte
$27.23 /

-0.54 (-1.94%)

SGEN Seagen
$132.55 /

+2.2 (+1.69%)

PFE Pfizer
$53.54 /

-0.58 (-1.07%)

NVS Novartis
$88.85 /

-0.7 (-0.78%)

MRTX Mirati Therapeutics
$120.93 /

+4.85 (+4.18%)

MRK Merck
$81.30 /

-0.25 (-0.31%)

LLY Eli Lilly
$245.08 /

-2.075 (-0.84%)

IPSEY Ipsen
$24.15 /

+0.4145 (+1.75%)

INCY Incyte
$74.81 /

-0.19 (-0.25%)

GH Guardant Health
$71.99 /

-0.48 (-0.66%)

EXEL Exelixis
$17.09 /

-0.28 (-1.61%)

EXAS Exact Sciences
$76.09 /

-1.24 (-1.60%)

DNA Ginkgo Bioworks
$5.04 /

-0.25 (-4.73%)

DCPH Deciphera
$8.50 /

+0.225 (+2.72%)

CRDF Cardiff Oncology
$4.54 /

-1.585 (-25.88%)

BMY Bristol-Myers
$64.73 /

-0.175 (-0.27%)

BAYRY Bayer
$14.82 /

+0.13 (+0.88%)

AZN AstraZeneca
$59.46 /

-0.37 (-0.62%)

AGEN Agenus
$2.82 /

-0.035 (-1.23%)

PFE Pfizer
$53.54 /

-0.58 (-1.07%)

NVS Novartis
$88.85 /

-0.7 (-0.78%)

MRK Merck
$81.30 /

-0.25 (-0.31%)

LLY Eli Lilly
$245.08 /

-2.075 (-0.84%)

INCY Incyte
$74.81 /

-0.19 (-0.25%)

DNA Ginkgo Bioworks
$5.04 /

-0.25 (-4.73%)

BMY Bristol-Myers
$64.73 /

-0.175 (-0.27%)

AZN AstraZeneca
$59.46 /

-0.37 (-0.62%)

AGEN Agenus
$2.82 /

-0.035 (-1.23%)

Wednesday
Hot Stocks
Regeneron's Libtayo combination for NSCLC accepted for review by FDA » 07:08
01/19/22
01/19
07:08
01/19/22
07:08
REGN

Regeneron

$611.66 /

-3.305 (-0.54%)

, SNY

Sanofi

$52.16 /

+0.225 (+0.43%)

Regeneron (REGN)…

Regeneron (REGN) announced that the FDA has accepted for review the supplemental Biologics License Application for PD-1 inhibitor Libtayoin combination with chemotherapy as first-line treatment in advanced non-small cell lung cancer, or NSCLC. The target action date for the FDA decision is September 19, 2022. The sBLA is supported by results from a randomized, multicenter Phase 3 trial that investigated Libtayo in combination with platinum-doublet chemotherapy, vs. platinum-doublet chemotherapy alone. A regulatory filing has also been recently submitted to the European Medicines Agency. The Phase 3 trial supporting the sBLA was stopped early after the Libtayo combination demonstrated a significant overall survival improvement compared to chemotherapy alone. In 2021, Libtayo was approved in the U.S. and European Union as first-line monotherapy treatment for adult patients with advanced NSCLC whose tumors have high PD-L1 expression. Libtayo, which was invented using Regeneron's proprietary VelocImmune(R) technology, is being jointly developed by Regeneron and Sanofi (SNY) under a global collaboration agreement.

ShowHide Related Items >><<
SNY Sanofi
$52.16 /

+0.225 (+0.43%)

REGN Regeneron
$611.66 /

-3.305 (-0.54%)

REGN Regeneron
$611.66 /

-3.305 (-0.54%)

01/05/22 BofA
Regeneron downgraded to Underperform at BofA on smaller REGEN-COV contribution
01/05/22 BofA
Regeneron downgraded to Underperform from Neutral at BofA
01/03/22 Bernstein
Regeneron upgraded to Outperform from Market Perform at Bernstein
12/30/21 SVB Leerink
SVB Leerink confident Adbry poses minimal competitive risk to Dupixent
SNY Sanofi
$52.16 /

+0.225 (+0.43%)

01/06/22 UBS
Sanofi price target raised to EUR 117 from EUR 116 at UBS
01/06/22 Stifel
Sangamo price target lowered to $6 from $9 at Stifel
12/21/21 Roth Capital
Sanofi deal for Amunix 'hints at' value of Harpoon platforms, says Roth Capital
SNY Sanofi
$52.16 /

+0.225 (+0.43%)

REGN Regeneron
$611.66 /

-3.305 (-0.54%)

SNY Sanofi
$52.16 /

+0.225 (+0.43%)

REGN Regeneron
$611.66 /

-3.305 (-0.54%)

SNY Sanofi
$52.16 /

+0.225 (+0.43%)

REGN Regeneron
$611.66 /

-3.305 (-0.54%)

REGN Regeneron
$611.66 /

-3.305 (-0.54%)

Hot Stocks
Regeneron, Sanofi announce PRIME trial meets primary and secondary endpoints » 05:35
01/19/22
01/19
05:35
01/19/22
05:35
REGN

Regeneron

$611.66 /

-3.305 (-0.54%)

, SNY

Sanofi

$52.16 /

+0.225 (+0.43%)

Regeneron (REGN) and…

Regeneron (REGN) and Sanofi (SNY) announced results from a second Phase 3 trial, PRIME, evaluating Dupixent in adults with uncontrolled prurigo nodularis, a chronic type 2 inflammatory skin disease. The trial met its primary and key secondary endpoints, showing that Dupixent significantly reduced itch and skin lesions compared to placebo at 24 weeks in this investigational setting. These data confirm the results that were previously reported from the Phase 3 PRIME2 trial, and are expected to be submitted to regulatory authorities around the world starting in the first half of this year. In the Phase 3 PRIME trial, topline results comparing Dupixent to placebo showed at week 24: More than three times as many Dupixent patients experienced a clinically meaningful reduction in itch from baseline, the primary endpoint: 60% of Dupixent patients compared to 18% of placebo patients. Nearly three times as many Dupixent patients achieved clear or almost clear skin, a key secondary endpoint: 48% of Dupixent patients compared to 18% of placebo patients. Dupixent patients experienced significantly greater improvements in measures of health-related quality of life, skin pain and symptoms of anxiety and depression. The safety results of the trial were consistent what was observed in PRIME2, and were also generally consistent with the known safety profile of Dupixent in its approved indications. For the 24-week treatment period, overall rates of treatment-emergent adverse events were 71% for Dupixent and 63% for placebo. Adverse events most commonly observed with Dupixent included nasopharyngitis and headache. Additionally, 0% of Dupixent patients and 4% of placebo patients discontinued treatment due to adverse events prior to week 24. Consistent with published literature for the atopic dermatitis trials, numerically lower rates of skin infections were seen with Dupixent in this trial. Detailed results from this trial will be presented at an upcoming medical congress. The potential use of Dupixent in prurigo nodularis is currently under clinical development, and the safety and efficacy have not been fully evaluated by any regulatory authority.

ShowHide Related Items >><<
SNY Sanofi
$52.16 /

+0.225 (+0.43%)

REGN Regeneron
$611.66 /

-3.305 (-0.54%)

REGN Regeneron
$611.66 /

-3.305 (-0.54%)

01/05/22 BofA
Regeneron downgraded to Underperform at BofA on smaller REGEN-COV contribution
01/05/22 BofA
Regeneron downgraded to Underperform from Neutral at BofA
01/03/22 Bernstein
Regeneron upgraded to Outperform from Market Perform at Bernstein
12/30/21 SVB Leerink
SVB Leerink confident Adbry poses minimal competitive risk to Dupixent
SNY Sanofi
$52.16 /

+0.225 (+0.43%)

01/06/22 UBS
Sanofi price target raised to EUR 117 from EUR 116 at UBS
01/06/22 Stifel
Sangamo price target lowered to $6 from $9 at Stifel
12/21/21 Roth Capital
Sanofi deal for Amunix 'hints at' value of Harpoon platforms, says Roth Capital
SNY Sanofi
$52.16 /

+0.225 (+0.43%)

REGN Regeneron
$611.66 /

-3.305 (-0.54%)

SNY Sanofi
$52.16 /

+0.225 (+0.43%)

REGN Regeneron
$611.66 /

-3.305 (-0.54%)

SNY Sanofi
$52.16 /

+0.225 (+0.43%)

REGN Regeneron
$611.66 /

-3.305 (-0.54%)

REGN Regeneron
$611.66 /

-3.305 (-0.54%)

Conference/Events
Demy-Colton & EBD Group to hold a virtual conference » 04:55
01/19/22
01/19
04:55
01/19/22
04:55
ALPMY

Astellas Pharma

$16.69 /

+0.18 (+1.09%)

, CGTX

Cognition Therapeutics

$5.45 /

-0.8 (-12.80%)

, CYBN

Cybin

$1.05 /

+ (+0.00%)

, CYCC

Cyclacel Pharmaceuticals

$3.54 /

-0.11 (-3.01%)

, GNPX

Genprex

$2.13 /

-0.135 (-5.97%)

, IMAB

I-Mab

$34.20 /

-0.83 (-2.37%)

, INAB

In8bio

$3.87 /

-0.06 (-1.53%)

, IQV

Iqvia

$242.40 /

-4.575 (-1.85%)

, JNJ

Johnson & Johnson

$167.22 /

-0.6 (-0.36%)

, LLY

Eli Lilly

$247.16 /

+3.045 (+1.25%)

, MRK

Merck

$81.55 /

+0.18 (+0.22%)

, NKTX

Nkarta

$11.22 /

-0.91 (-7.50%)

, NVO

Novo Nordisk

$96.39 /

+0.12 (+0.12%)

, OPY

Oppenheimer Holdings

$44.94 /

-1.34 (-2.90%)

, SYNH

Syneos Health

$86.06 /

-3.9 (-4.34%)

, XOMA

Xoma

$20.96 /

-1.09 (-4.94%)

Digital Medicine &…

Digital Medicine & Medtech Showcase Virtual Conference to be held on January 17-19.Webcast Link

ShowHide Related Items >><<
XOMA Xoma
$20.96 /

-1.09 (-4.94%)

SYNH Syneos Health
$86.06 /

-3.9 (-4.34%)

OPY Oppenheimer Holdings
$44.94 /

-1.34 (-2.90%)

NVO Novo Nordisk
$96.39 /

+0.12 (+0.12%)

NKTX Nkarta
$11.22 /

-0.91 (-7.50%)

MRK Merck
$81.55 /

+0.18 (+0.22%)

LLY Eli Lilly
$247.16 /

+3.045 (+1.25%)

JNJ Johnson & Johnson
$167.22 /

-0.6 (-0.36%)

IQV Iqvia
$242.40 /

-4.575 (-1.85%)

INAB In8bio
$3.87 /

-0.06 (-1.53%)

IMAB I-Mab
$34.20 /

-0.83 (-2.37%)

GNPX Genprex
$2.13 /

-0.135 (-5.97%)

CYCC Cyclacel Pharmaceuticals
$3.54 /

-0.11 (-3.01%)

CYBN Cybin
$1.05 /

+ (+0.00%)

CGTX Cognition Therapeutics
$5.45 /

-0.8 (-12.80%)

ALPMY Astellas Pharma
$16.69 /

+0.18 (+1.09%)

ALPMY Astellas Pharma
$16.69 /

+0.18 (+1.09%)

06/29/21 Jefferies
Astellas Pharma downgraded to Hold from Buy at Jefferies
CGTX Cognition Therapeutics
$5.45 /

-0.8 (-12.80%)

11/03/21
Fly Intel: Top five analyst initiations
11/03/21 B. Riley
Cognition Therapeutics initiated with a Buy at B. Riley
11/03/21 Oppenheimer
Cognition Therapeutics initiated with an Outperform at Oppenheimer
CYBN Cybin
$1.05 /

+ (+0.00%)

11/23/21 Stifel
Cybin price target lowered to C$8.25 from C$10 at Stifel
11/22/21 H.C. Wainwright
Cybin price target raised to $10 from $8 at H.C. Wainwright
11/19/21 Maxim
Cybin downgraded to Hold from Buy at Maxim
11/19/21 Maxim
Cybin downgraded to Hold from Buy at Maxim
CYCC Cyclacel Pharmaceuticals
$3.54 /

-0.11 (-3.01%)

11/18/21 Ladenburg
Cyclacel Pharmaceuticals price target lowered to $17 from $18 at Ladenburg
04/30/21
Fly Intel: Top five analyst initiations
04/30/21 Oppenheimer
Cyclacel Pharmaceuticals initiated with an Outperform at Oppenheimer
04/29/21 Oppenheimer
Cyclacel Pharmaceuticals initiated with an Outperform at Oppenheimer
GNPX Genprex
$2.13 /

-0.135 (-5.97%)

01/26/21 National Securities
Genprex initiated with a Buy at National Securities
IMAB I-Mab
$34.20 /

-0.83 (-2.37%)

09/03/21 Cantor Fitzgerald
Cantor Fitzgerald positive on I-Mab following 'solid' first half
09/01/21 H.C. Wainwright
I-Mab price target raised to $95 from $75 at H.C. Wainwright
07/26/21 Cantor Fitzgerald
I-Mab's overdone weakness a buying opportunity, says Cantor Fitzgerald
07/13/21 Cantor Fitzgerald
I-Mab price target raised to $95 from $90 at Cantor Fitzgerald
INAB In8bio
$3.87 /

-0.06 (-1.53%)

08/24/21 Mizuho
In8bio initiated with a Buy at Mizuho
08/23/21 B. Riley
In8bio initiated with a Buy on cancer potential at B. Riley
08/23/21 B. Riley
In8bio initiated with a Buy at B. Riley
IQV Iqvia
$242.40 /

-4.575 (-1.85%)

01/06/22 UBS
Iqvia named 2022 top pick at UBS
12/23/21 JPMorgan
Iqvia long-term sales outlook tops expectations, says JPMorgan
12/20/21 Mizuho
Iqvia price target raised to $300 from $290 at Mizuho
11/18/21 BofA
Iqvia added to US 1 list at BofA
JNJ Johnson & Johnson
$167.22 /

-0.6 (-0.36%)

12/29/21 Credit Suisse
Credit Suisse reiterates Outperform on J&J as trends point to pharma upside
12/17/21
Fly Intel: Top five analyst initiations
12/17/21 Goldman Sachs
Goldman starts Johnson & Johnson at Neutral amid disruption risk
12/17/21 Goldman Sachs
Johnson & Johnson initiated with a Neutral at Goldman Sachs
LLY Eli Lilly
$247.16 /

+3.045 (+1.25%)

01/14/22 BofA
Biogen price target lowered to $245 from $275 at BofA
01/12/22 Wells Fargo
CMS proposed coverage with evidence 'a clear negative,' says Wells Fargo
01/05/22 Mizuho
Eli Lilly price target raised to $302 from $272 at Mizuho
01/04/22 Wells Fargo
Eli Lilly price target raised to $280 from $270 at Wells Fargo
MRK Merck
$81.55 /

+0.18 (+0.22%)

12/23/21 Mizuho
Mizuho sees market for both Merck's molnupiravir, Pfizer's Paxlovid
12/17/21 Goldman Sachs
Goldman starts Merck at Conviction Buy with market undervaluing assets
12/17/21 Goldman Sachs
Merck initiated with a Conviction Buy at Goldman Sachs
12/16/21 Daiwa
Merck initiated with a Neutral at Daiwa
NKTX Nkarta
$11.22 /

-0.91 (-7.50%)

01/06/22 William Blair
Nkarta initiated with an Outperform at William Blair
11/18/21 SMBC Nikko
Nkarta initiated with an Outperform at SMBC Nikko
07/15/21 Oppenheimer
Nkarta initiated with an Outperform at Oppenheimer
06/29/21 Cantor Fitzgerald
Nkarta price target lowered to $71 from $78 at Cantor Fitzgerald
NVO Novo Nordisk
$96.39 /

+0.12 (+0.12%)

01/06/22 Wedbush
Wedbush bullish on 2seventy Bio as partnerships add free upside in Hem-A
12/21/21 Jefferies
Catalent reaction to Novo Nordisk news 'seems slightly overdone,' says Jefferies
12/21/21 JPMorgan
Catalent recent selloff a buying opportunity, says JPMorgan
12/20/21 Citi
Citi downgrades Novo Nordisk to Neutral on Wegovy supply issues
OPY Oppenheimer Holdings
$44.94 /

-1.34 (-2.90%)

SYNH Syneos Health
$86.06 /

-3.9 (-4.34%)

12/15/21 Citi
Syneos Health downgraded to Neutral from Buy at Citi
11/04/21 Baird
Syneos Health price target raised to $122 from $115 at Baird
11/04/21 Barclays
Syneos Health upgraded to Overweight from Equal Weight at Barclays
08/04/21 Credit Suisse
Syneos Health assumed with an Outperform at Credit Suisse
XOMA Xoma
$20.96 /

-1.09 (-4.94%)

10/08/21 H.C. Wainwright
Xoma price target raised to $69 from $56 at H.C. Wainwright
09/07/21 Wedbush
Wedbush downgrades Xoma to Neutral, cuts target to $22
09/07/21 Wedbush
Xoma downgraded to Neutral from Outperform at Wedbush
06/29/21 Aegis
Xoma initiated with a Buy at Aegis
XOMA Xoma
$20.96 /

-1.09 (-4.94%)

SYNH Syneos Health
$86.06 /

-3.9 (-4.34%)

NVO Novo Nordisk
$96.39 /

+0.12 (+0.12%)

NKTX Nkarta
$11.22 /

-0.91 (-7.50%)

MRK Merck
$81.55 /

+0.18 (+0.22%)

LLY Eli Lilly
$247.16 /

+3.045 (+1.25%)

JNJ Johnson & Johnson
$167.22 /

-0.6 (-0.36%)

IQV Iqvia
$242.40 /

-4.575 (-1.85%)

CYCC Cyclacel Pharmaceuticals
$3.54 /

-0.11 (-3.01%)

CGTX Cognition Therapeutics
$5.45 /

-0.8 (-12.80%)

  • 30
    Nov
  • 08
    Oct
  • 30
    Jul
  • 03
    Jun
  • 04
    May
  • 12
    Mar
  • 01
    Mar
  • 09
    Feb
SYNH Syneos Health
$86.06 /

-3.9 (-4.34%)

MRK Merck
$81.55 /

+0.18 (+0.22%)

LLY Eli Lilly
$247.16 /

+3.045 (+1.25%)

JNJ Johnson & Johnson
$167.22 /

-0.6 (-0.36%)

SYNH Syneos Health
$86.06 /

-3.9 (-4.34%)

NVO Novo Nordisk
$96.39 /

+0.12 (+0.12%)

MRK Merck
$81.55 /

+0.18 (+0.22%)

LLY Eli Lilly
$247.16 /

+3.045 (+1.25%)

JNJ Johnson & Johnson
$167.22 /

-0.6 (-0.36%)

IQV Iqvia
$242.40 /

-4.575 (-1.85%)

INAB In8bio
$3.87 /

-0.06 (-1.53%)

CYBN Cybin
$1.05 /

+ (+0.00%)

CGTX Cognition Therapeutics
$5.45 /

-0.8 (-12.80%)

ALPMY Astellas Pharma
$16.69 /

+0.18 (+1.09%)

XOMA Xoma
$20.96 /

-1.09 (-4.94%)

NVO Novo Nordisk
$96.39 /

+0.12 (+0.12%)

MRK Merck
$81.55 /

+0.18 (+0.22%)

LLY Eli Lilly
$247.16 /

+3.045 (+1.25%)

JNJ Johnson & Johnson
$167.22 /

-0.6 (-0.36%)

Tuesday
Conference/Events
Demy-Colton & EBD Group to hold a virtual conference » 09:19
01/18/22
01/18
09:19
01/18/22
09:19
ALPMY

Astellas Pharma

$16.51 /

+0.05 (+0.30%)

, CGTX

Cognition Therapeutics

$6.25 /

-0.21 (-3.25%)

, CYBN

Cybin

$1.05 /

+0.015 (+1.46%)

, CYCC

Cyclacel Pharmaceuticals

$3.64 /

+0.07 (+1.96%)

, GNPX

Genprex

$2.26 /

-0.01 (-0.44%)

, IMAB

I-Mab

$35.09 /

-0.29 (-0.82%)

, INAB

In8bio

$3.97 /

-0.28 (-6.59%)

, IQV

Iqvia

$247.24 /

-4.81 (-1.91%)

, JNJ

Johnson & Johnson

$167.82 /

-0.96 (-0.57%)

, LLY

Eli Lilly

$244.09 /

-4.775 (-1.92%)

, MRK

Merck

$81.37 /

+0.03 (+0.04%)

, NKTX

Nkarta

$12.18 /

-0.1 (-0.81%)

, NVO

Novo Nordisk

$96.27 /

-3.13 (-3.15%)

, OPY

Oppenheimer Holdings

$46.46 /

-1.39 (-2.90%)

, SYNH

Syneos Health

$89.96 /

-2.31 (-2.50%)

, XOMA

Xoma

$22.11 /

-0.17 (-0.76%)

Digital Medicine &…

Digital Medicine & Medtech Showcase Virtual Conference to be held on January 17-19.Webcast Link

ShowHide Related Items >><<
XOMA Xoma
$22.11 /

-0.17 (-0.76%)

SYNH Syneos Health
$89.96 /

-2.31 (-2.50%)

OPY Oppenheimer Holdings
$46.46 /

-1.39 (-2.90%)

NVO Novo Nordisk
$96.27 /

-3.13 (-3.15%)

NKTX Nkarta
$12.18 /

-0.1 (-0.81%)

MRK Merck
$81.37 /

+0.03 (+0.04%)

LLY Eli Lilly
$244.09 /

-4.775 (-1.92%)

JNJ Johnson & Johnson
$167.82 /

-0.96 (-0.57%)

IQV Iqvia
$247.24 /

-4.81 (-1.91%)

INAB In8bio
$3.97 /

-0.28 (-6.59%)

IMAB I-Mab
$35.09 /

-0.29 (-0.82%)

GNPX Genprex
$2.26 /

-0.01 (-0.44%)

CYCC Cyclacel Pharmaceuticals
$3.64 /

+0.07 (+1.96%)

CYBN Cybin
$1.05 /

+0.015 (+1.46%)

CGTX Cognition Therapeutics
$6.25 /

-0.21 (-3.25%)

ALPMY Astellas Pharma
$16.51 /

+0.05 (+0.30%)

ALPMY Astellas Pharma
$16.51 /

+0.05 (+0.30%)

06/29/21 Jefferies
Astellas Pharma downgraded to Hold from Buy at Jefferies
CGTX Cognition Therapeutics
$6.25 /

-0.21 (-3.25%)

11/03/21
Fly Intel: Top five analyst initiations
11/03/21 B. Riley
Cognition Therapeutics initiated with a Buy at B. Riley
11/03/21 Oppenheimer
Cognition Therapeutics initiated with an Outperform at Oppenheimer
CYBN Cybin
$1.05 /

+0.015 (+1.46%)

11/23/21 Stifel
Cybin price target lowered to C$8.25 from C$10 at Stifel
11/22/21 H.C. Wainwright
Cybin price target raised to $10 from $8 at H.C. Wainwright
11/19/21 Maxim
Cybin downgraded to Hold from Buy at Maxim
11/19/21 Maxim
Cybin downgraded to Hold from Buy at Maxim
CYCC Cyclacel Pharmaceuticals
$3.64 /

+0.07 (+1.96%)

11/18/21 Ladenburg
Cyclacel Pharmaceuticals price target lowered to $17 from $18 at Ladenburg
04/30/21
Fly Intel: Top five analyst initiations
04/30/21 Oppenheimer
Cyclacel Pharmaceuticals initiated with an Outperform at Oppenheimer
04/29/21 Oppenheimer
Cyclacel Pharmaceuticals initiated with an Outperform at Oppenheimer
GNPX Genprex
$2.26 /

-0.01 (-0.44%)

01/26/21 National Securities
Genprex initiated with a Buy at National Securities
IMAB I-Mab
$35.09 /

-0.29 (-0.82%)

09/03/21 Cantor Fitzgerald
Cantor Fitzgerald positive on I-Mab following 'solid' first half
09/01/21 H.C. Wainwright
I-Mab price target raised to $95 from $75 at H.C. Wainwright
07/26/21 Cantor Fitzgerald
I-Mab's overdone weakness a buying opportunity, says Cantor Fitzgerald
07/13/21 Cantor Fitzgerald
I-Mab price target raised to $95 from $90 at Cantor Fitzgerald
INAB In8bio
$3.97 /

-0.28 (-6.59%)

08/24/21 Mizuho
In8bio initiated with a Buy at Mizuho
08/23/21 B. Riley
In8bio initiated with a Buy on cancer potential at B. Riley
08/23/21 B. Riley
In8bio initiated with a Buy at B. Riley
IQV Iqvia
$247.24 /

-4.81 (-1.91%)

01/06/22 UBS
Iqvia named 2022 top pick at UBS
12/23/21 JPMorgan
Iqvia long-term sales outlook tops expectations, says JPMorgan
12/20/21 Mizuho
Iqvia price target raised to $300 from $290 at Mizuho
11/18/21 BofA
Iqvia added to US 1 list at BofA
JNJ Johnson & Johnson
$167.82 /

-0.96 (-0.57%)

12/29/21 Credit Suisse
Credit Suisse reiterates Outperform on J&J as trends point to pharma upside
12/17/21
Fly Intel: Top five analyst initiations
12/17/21 Goldman Sachs
Goldman starts Johnson & Johnson at Neutral amid disruption risk
12/17/21 Goldman Sachs
Johnson & Johnson initiated with a Neutral at Goldman Sachs
LLY Eli Lilly
$244.09 /

-4.775 (-1.92%)

01/14/22 BofA
Biogen price target lowered to $245 from $275 at BofA
01/12/22 Wells Fargo
CMS proposed coverage with evidence 'a clear negative,' says Wells Fargo
01/05/22 Mizuho
Eli Lilly price target raised to $302 from $272 at Mizuho
01/04/22 Wells Fargo
Eli Lilly price target raised to $280 from $270 at Wells Fargo
MRK Merck
$81.37 /

+0.03 (+0.04%)

12/23/21 Mizuho
Mizuho sees market for both Merck's molnupiravir, Pfizer's Paxlovid
12/17/21 Goldman Sachs
Goldman starts Merck at Conviction Buy with market undervaluing assets
12/17/21 Goldman Sachs
Merck initiated with a Conviction Buy at Goldman Sachs
12/16/21 Daiwa
Merck initiated with a Neutral at Daiwa
NKTX Nkarta
$12.18 /

-0.1 (-0.81%)

01/06/22 William Blair
Nkarta initiated with an Outperform at William Blair
11/18/21 SMBC Nikko
Nkarta initiated with an Outperform at SMBC Nikko
07/15/21 Oppenheimer
Nkarta initiated with an Outperform at Oppenheimer
06/29/21 Cantor Fitzgerald
Nkarta price target lowered to $71 from $78 at Cantor Fitzgerald
NVO Novo Nordisk
$96.27 /

-3.13 (-3.15%)

01/06/22 Wedbush
Wedbush bullish on 2seventy Bio as partnerships add free upside in Hem-A
12/21/21 Jefferies
Catalent reaction to Novo Nordisk news 'seems slightly overdone,' says Jefferies
12/21/21 JPMorgan
Catalent recent selloff a buying opportunity, says JPMorgan
12/20/21 Citi
Citi downgrades Novo Nordisk to Neutral on Wegovy supply issues
OPY Oppenheimer Holdings
$46.46 /

-1.39 (-2.90%)

SYNH Syneos Health
$89.96 /

-2.31 (-2.50%)

12/15/21 Citi
Syneos Health downgraded to Neutral from Buy at Citi
11/04/21 Baird
Syneos Health price target raised to $122 from $115 at Baird
11/04/21 Barclays
Syneos Health upgraded to Overweight from Equal Weight at Barclays
08/04/21 Credit Suisse
Syneos Health assumed with an Outperform at Credit Suisse
XOMA Xoma
$22.11 /

-0.17 (-0.76%)

10/08/21 H.C. Wainwright
Xoma price target raised to $69 from $56 at H.C. Wainwright
09/07/21 Wedbush
Wedbush downgrades Xoma to Neutral, cuts target to $22
09/07/21 Wedbush
Xoma downgraded to Neutral from Outperform at Wedbush
06/29/21 Aegis
Xoma initiated with a Buy at Aegis
XOMA Xoma
$22.11 /

-0.17 (-0.76%)

SYNH Syneos Health
$89.96 /

-2.31 (-2.50%)

NVO Novo Nordisk
$96.27 /

-3.13 (-3.15%)

NKTX Nkarta
$12.18 /

-0.1 (-0.81%)

MRK Merck
$81.37 /

+0.03 (+0.04%)

LLY Eli Lilly
$244.09 /

-4.775 (-1.92%)

JNJ Johnson & Johnson
$167.82 /

-0.96 (-0.57%)

IQV Iqvia
$247.24 /

-4.81 (-1.91%)

CYCC Cyclacel Pharmaceuticals
$3.64 /

+0.07 (+1.96%)

CGTX Cognition Therapeutics
$6.25 /

-0.21 (-3.25%)

  • 30
    Nov
  • 08
    Oct
  • 30
    Jul
  • 03
    Jun
  • 04
    May
  • 12
    Mar
  • 01
    Mar
  • 09
    Feb
SYNH Syneos Health
$89.96 /

-2.31 (-2.50%)

MRK Merck
$81.37 /

+0.03 (+0.04%)

LLY Eli Lilly
$244.09 /

-4.775 (-1.92%)

JNJ Johnson & Johnson
$167.82 /

-0.96 (-0.57%)

SYNH Syneos Health
$89.96 /

-2.31 (-2.50%)

NVO Novo Nordisk
$96.27 /

-3.13 (-3.15%)

MRK Merck
$81.37 /

+0.03 (+0.04%)

LLY Eli Lilly
$244.09 /

-4.775 (-1.92%)

JNJ Johnson & Johnson
$167.82 /

-0.96 (-0.57%)

IQV Iqvia
$247.24 /

-4.81 (-1.91%)

INAB In8bio
$3.97 /

-0.28 (-6.59%)

CYBN Cybin
$1.05 /

+0.015 (+1.46%)

CGTX Cognition Therapeutics
$6.25 /

-0.21 (-3.25%)

ALPMY Astellas Pharma
$16.51 /

+0.05 (+0.30%)

XOMA Xoma
$22.11 /

-0.17 (-0.76%)

NVO Novo Nordisk
$96.27 /

-3.13 (-3.15%)

MRK Merck
$81.37 /

+0.03 (+0.04%)

LLY Eli Lilly
$244.09 /

-4.775 (-1.92%)

JNJ Johnson & Johnson
$167.82 /

-0.96 (-0.57%)

Over a week ago
Recommendations
Biogen price target lowered to $245 from $275 at BofA » 07:28
01/14/22
01/14
07:28
01/14/22
07:28
BIIB

Biogen

/

+

, LLY

Eli Lilly

$249.21 /

-6.57 (-2.57%)

, RHHBY

Roche

$49.48 /

-0.62 (-1.24%)

BofA analyst Geoff…

BofA analyst Geoff Meacham lowered the firm's price target on Biogen (BIIB) to $245 from $275 and keeps a Neutral rating on the shares, stating that he suspects investors have largely removed Aduhelm from models at this point after CMS posted its anticipated draft NCD for anti-amyloid-beta mAbs treatments and established what in his view is a restrictive coverage policy. Biogen does have "a second shot on goal in Alzheimer's" with lecanemab, but Meacham said its difficult for him to envision a scenario in which Biogen can capture meaningful share against "more commercially capable" Eli Lilly (LLY) and Roche (RHHBY), whose assets appear to him to have stronger product profiles.

ShowHide Related Items >><<
RHHBY Roche
$49.48 /

-0.62 (-1.24%)

LLY Eli Lilly
$249.21 /

-6.57 (-2.57%)

BIIB Biogen
/

+

BIIB Biogen
/

+

01/13/22 Guggenheim
Biogen downgraded to Neutral from Buy at Guggenheim
01/13/22 Guggenheim
Biogen downgraded to Neutral from Buy at Guggenheim
01/12/22 Stifel
Stifel says Biogen BAN2401 data the 'big 2022 event' after 'big blow' to Aduhelm
01/12/22 Wedbush
Biogen price target lowered to $195 from $249 at Wedbush
LLY Eli Lilly
$249.21 /

-6.57 (-2.57%)

01/12/22 Wells Fargo
CMS proposed coverage with evidence 'a clear negative,' says Wells Fargo
01/05/22 Mizuho
Eli Lilly price target raised to $302 from $272 at Mizuho
01/04/22 Wells Fargo
Eli Lilly price target raised to $280 from $270 at Wells Fargo
12/20/21 Berenberg
Eli Lilly price target raised to $305 from $270 at Berenberg
RHHBY Roche
$49.48 /

-0.62 (-1.24%)

01/04/22 JPMorgan
Roche price target raised to CHF 390 from CHF 360 at JPMorgan
12/22/21 Citi
Roche resumed with a Buy at Citi
12/13/21 Credit Suisse
Roche price target raised to CHF 370 from CHF 350 at Credit Suisse
12/07/21 Jefferies
AstraZeneca downgraded to Hold from Buy at Jefferies
RHHBY Roche
$49.48 /

-0.62 (-1.24%)

LLY Eli Lilly
$249.21 /

-6.57 (-2.57%)

BIIB Biogen
/

+

RHHBY Roche
$49.48 /

-0.62 (-1.24%)

LLY Eli Lilly
$249.21 /

-6.57 (-2.57%)

BIIB Biogen
/

+

RHHBY Roche
$49.48 /

-0.62 (-1.24%)

LLY Eli Lilly
$249.21 /

-6.57 (-2.57%)

BIIB Biogen
/

+

LLY Eli Lilly
$249.21 /

-6.57 (-2.57%)

BIIB Biogen
/

+

On The Fly
Meet Prothena: Fly exclusive interview with CEO Gene Kinney » 13:02
01/13/22
01/13
13:02
01/13/22
13:02
PRTA

Prothena

$36.77 /

-0.58 (-1.55%)

, BIIB

Biogen

$238.08 /

+12.76 (+5.66%)

, LLY

Eli Lilly

$250.70 /

-5.08 (-1.99%)

, RHHBY

Roche

$50.10 /

-0.91 (-1.78%)

, BMY

Bristol-Myers

$64.81 /

-0.03 (-0.05%)

In an exclusive interview…

ShowHide Related Items >><<
RHHBY Roche
$50.10 /

-0.91 (-1.78%)

PRTA Prothena
$36.77 /

-0.58 (-1.55%)

LLY Eli Lilly
$250.70 /

-5.08 (-1.99%)

BMY Bristol-Myers
$64.81 /

-0.03 (-0.05%)

BIIB Biogen
$238.08 /

+12.76 (+5.66%)

PRTA Prothena
$36.77 /

-0.58 (-1.55%)

11/19/21 JMP Securities
Prothena initiated with an Outperform at JMP Securities
09/30/21 RBC Capital
Prothena price target raised to $82 from $59 at RBC Capital
09/27/21 Oppenheimer
Prothena price target raised to $100 from $90 at Oppenheimer
09/20/21 Fox Advisors
Prothena initiated with an Overweight at Fox Advisors
BIIB Biogen
$238.08 /

+12.76 (+5.66%)

01/14/22 Jefferies
Biogen remains 'open to all options on the table,' says Jefferies
01/14/22 BofA
Biogen price target lowered to $245 from $275 at BofA
01/13/22 Guggenheim
Biogen downgraded to Neutral from Buy at Guggenheim
01/13/22 Guggenheim
Biogen downgraded to Neutral from Buy at Guggenheim
LLY Eli Lilly
$250.70 /

-5.08 (-1.99%)

01/12/22 Wells Fargo
CMS proposed coverage with evidence 'a clear negative,' says Wells Fargo
01/05/22 Mizuho
Eli Lilly price target raised to $302 from $272 at Mizuho
01/04/22 Wells Fargo
Eli Lilly price target raised to $280 from $270 at Wells Fargo
RHHBY Roche
$50.10 /

-0.91 (-1.78%)

01/04/22 JPMorgan
Roche price target raised to CHF 390 from CHF 360 at JPMorgan
12/22/21 Citi
Roche resumed with a Buy at Citi
12/13/21 Credit Suisse
Roche price target raised to CHF 370 from CHF 350 at Credit Suisse
BMY Bristol-Myers
$64.81 /

-0.03 (-0.05%)

01/10/22 Piper Sandler
Piper says Century Therapeutics' alliance with Bristol 'transformational'
01/03/22 Piper Sandler
Legend Biotech named a top pick for 2022 at Piper Sandler
12/21/21 Oppenheimer
Oppenheimer starts Cytokinetics at Outperform, sees 'blockbuster' potential
12/21/21 Piper Sandler
Legend Biotech initiated with an Overweight at Piper Sandler
RHHBY Roche
$50.10 /

-0.91 (-1.78%)

PRTA Prothena
$36.77 /

-0.58 (-1.55%)

LLY Eli Lilly
$250.70 /

-5.08 (-1.99%)

BMY Bristol-Myers
$64.81 /

-0.03 (-0.05%)

BIIB Biogen
$238.08 /

+12.76 (+5.66%)

  • 24
    Mar
RHHBY Roche
$50.10 /

-0.91 (-1.78%)

LLY Eli Lilly
$250.70 /

-5.08 (-1.99%)

BMY Bristol-Myers
$64.81 /

-0.03 (-0.05%)

BIIB Biogen
$238.08 /

+12.76 (+5.66%)

RHHBY Roche
$50.10 /

-0.91 (-1.78%)

PRTA Prothena
$36.77 /

-0.58 (-1.55%)

LLY Eli Lilly
$250.70 /

-5.08 (-1.99%)

BMY Bristol-Myers
$64.81 /

-0.03 (-0.05%)

BIIB Biogen
$238.08 /

+12.76 (+5.66%)

LLY Eli Lilly
$250.70 /

-5.08 (-1.99%)

BMY Bristol-Myers
$64.81 /

-0.03 (-0.05%)

BIIB Biogen
$238.08 /

+12.76 (+5.66%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.